id,evidence_inference_prompt_id,pmcid,outcome,intervention,comparator agent,effect_label,effect_label_code,outcome_type,intervention_events,intervention_group_size,comparator_events,comparator_group_size,intervention_mean,intervention_standard_deviation,comparator_mean,comparator_standard_deviation,standardized_mean_difference,smd_sampling_variance,log_odds_ratio,lor_sampling_variance,log_risk_ratio,lrr_sampling_variance,notes,is_data_in_figure_graphics,is_relevant_data_in_table,is_table_in_graphic_format,is_data_complete,openai_gpt_token_num_abstract_results,split,annotator_initials
1,11248,57750,Death or myocardial infarction,eptifibatide,placebo,significantly decreased,-1,binary,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Group sizes are not given so the events cannot calculate using the percentages.,FALSE,FALSE,FALSE,FALSE,"5,811",DEV,HY
2,11249,57750,Myocardial infarction,eptifibatide,placebo,no significant difference,0,binary,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Group sizes are not given so the events cannot calculate using the percentages.,FALSE,FALSE,FALSE,FALSE,"5,811",DEV,HY
3,11266,1216327,The mean body weight gain,White Grape Juice (WGJ),colored and flavored water (WA),no significant difference,0,continuous,,30,,30,50.6,,-0.7,,cannot calculate,cannot calculate,,,,,Missing standard deviations,FALSE,TRUE,FALSE,FALSE,"6,350",DEV,HY
4,11267,1216327,The duration of the illness,White Grape Juice (WGJ),colored and flavored water (WA),significantly increased,1,continuous,,30,,30,47.5,38.9,26.5,27.4,0.6161,0.0698,,,,,,FALSE,TRUE,FALSE,TRUE,"6,350",DEV,HY
5,11268,1216327,The fecal losses,White Grape Juice (WGJ),colored and flavored water (WA),significantly increased,1,continuous,,30,,30,3.59,2.35,2.19,1.63,0.6833,0.0706,,,,,,FALSE,TRUE,FALSE,TRUE,"6,350",DEV,HY
6,11451,1574360,The amount of saturated fat in the foods purchased,fully automated advice that recommended specific switches from selected products higher in saturated fat to alternate similar products lower in saturated fat,control received general non-specific advice about how to eat a diet lower in saturated fat,significantly decreased,-1,continuous,,251,,246,0.77,1.37,0.04,0.32,0.7273,0.0086,,,,,Have to use CI to calculate the SDs,FALSE,FALSE,TRUE,TRUE,"1,959",TEST,HY
7,11452,1574360,the average cost of the food,fully automated advice that recommended specific switches from selected products higher in saturated fat to alternate similar products lower in saturated fat,control received general non-specific advice about how to eat a diet lower in saturated fat,no significant difference,0,continuous,,251,,246,0.63,0.4,0.62,0.36,0.0261,0.008,,,,,Have to use CI to calculate the SDs,FALSE,FALSE,TRUE,TRUE,"1,959",TEST,HY
8,9683,2363753,Days with fever,Amifostine,Control,significantly decreased,-1,continuous,,20,,20,,,,,cannot calculate,cannot calculate,,,,,Only abstract is available. Full text in PDF only.,FALSE,FALSE,FALSE,FALSE,887,TEST,HY
9,9684,2363753,Hospital stay,Amifostine,Control,significantly decreased,-1,continuous,,20,,20,,,,,cannot calculate,cannot calculate,,,,,Only abstract is available. Full text in PDF only.,FALSE,FALSE,FALSE,FALSE,887,TEST,HY
10,9682,2363753,Grade III/IV stomatitis,Amifostine,Control,significantly decreased,-1,binary,0,20,5,20,,,,,,,-2.6775,2.2951,-2.3979,2.0866,Only abstract is available. Full text in PDF only.,FALSE,FALSE,FALSE,TRUE,887,TEST,HY
11,9681,2363753,Glomerular filtration rate fall,Amifostine,Control,significantly decreased,-1,continuous,,20,,20,10,,37,,cannot calculate,cannot calculate,,,,,Only abstract is available. Full text in PDF only.,FALSE,FALSE,FALSE,FALSE,887,TEST,HY
12,12632,2667135,number of days with received courses of antibiotics,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,significantly increased,1,continuous,,103,,97,25.4,,13.5,,cannot calculate,cannot calculate,,,,,SD or CI is missing. Mean is given.,FALSE,FALSE,FALSE,FALSE,"11,722",TEST,HY
13,12633,2667135,proportion of patients completed therapy,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,significantly increased,1,binary,93,103,44,97,,,,,,,2.4161,0.1523,0.6884,0.0135,,FALSE,TRUE,FALSE,TRUE,"11,722",TEST,HY
14,12634,2667135,early discontinuations,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,significantly decreased,-1,binary,10,103,54,97,,,,,,,-2.4161,0.1523,-1.7277,0.0988,,FALSE,TRUE,FALSE,TRUE,"11,722",TEST,HY
15,12635,2667135,rate of clinical success at the test-of-cure visit,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,significantly increased,1,binary,89,103,54,97,,,,,,,1.6218,0.1244,0.4396,0.0097,,FALSE,TRUE,FALSE,TRUE,"11,722",TEST,HY
16,12636,2667135,deaths,some portion of therapy outside of the hospital (CoPAT),full course of therapy in the hospital setting,significantly decreased,-1,binary,4,103,18,97,,,,,,,-1.7297,0.3283,-1.5641,0.2855,,FALSE,TRUE,FALSE,TRUE,"11,722",TEST,HY
17,8237,2681019,Adiponectin in women,Red wine,Control,significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Mean and SD in figure. Group sizes not available in results section.,TRUE,FALSE,FALSE,FALSE,726,DEV,HY
18,8238,2681019,Adiponectin in men,Ethanol solution,Control,significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Mean and SD in figure. Group sizes not available in results section.,TRUE,FALSE,FALSE,FALSE,726,DEV,HY
19,8239,2681019,Adiponectin in men,Beer,Control,significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Mean and SD in figure. Group sizes not available in results section.,TRUE,FALSE,FALSE,FALSE,726,DEV,HY
20,3246,2972614,Adverse effects,Laser therapy (Group I),Placebo laser therapy (Group II),no significant difference,0,binary,0,30,0,22,,,,,,,-0.3042,4.0772,-0.2985,3.9243,,FALSE,FALSE,FALSE,TRUE,"7,041",TEST,HY
21,3243,2972614,Severity of pain,Laser therapy (Group I),Placebo laser therapy (Group II),no significant difference,0,continuous,,30,,22,3.76,1.45,4.63,2.1,-0.4889,0.0811,,,,,,FALSE,TRUE,FALSE,TRUE,"7,041",TEST,HY
22,3245,2972614,Shoulder Pain and Disability Index score,Laser therapy (Group I),Placebo laser therapy (Group II),no significant difference,0,continuous,,30,,22,48.13,22.1,40.99,20.98,0.325,0.0798,,,,,,FALSE,TRUE,FALSE,TRUE,"7,041",TEST,HY
23,3247,2972614,Laboratory parameters,Laser therapy (Group I),Placebo laser therapy (Group II),no significant difference,0,continuous,,30,,22,,,,,cannot calculate,cannot calculate,,,,,Unclear outcome and also no numerical data for this specific outcome,FALSE,FALSE,FALSE,FALSE,"7,041",TEST,HY
24,3244,2972614,Motion range - Shoulder flexion,Laser therapy (Group I),Placebo laser therapy (Group II),no significant difference,0,continuous,,30,,22,168,22.65,174.31,14.98,-0.314,0.0797,,,,,Outcome originally just Motion range.,FALSE,TRUE,FALSE,FALSE,"7,041",TEST,HY
25,3244,2972614,Motion range - Shoulder extension,Laser therapy (Group I),Placebo laser therapy (Group II),no significant difference,0,continuous,,30,,22,42.66,3.4,42.95,3.98,-0.0781,0.0788,,,,,Outcome originally just Motion range.,FALSE,TRUE,FALSE,FALSE,"7,041",TEST,HY
26,3244,2972614,Motion range - Shoulder abduction,Laser therapy (Group I),Placebo laser therapy (Group II),no significant difference,0,continuous,,30,,22,166.66,21.38,172.72,16.67,-0.3054,0.0797,,,,,Outcome originally just Motion range.,FALSE,TRUE,FALSE,FALSE,"7,041",TEST,HY
27,3244,2972614,Motion range - Shoulder adduction,Laser therapy (Group I),Placebo laser therapy (Group II),no significant difference,0,continuous,,30,,22,42,4.27,42.04,5.26,-0.0084,0.0788,,,,,Outcome originally just Motion range.,FALSE,TRUE,FALSE,FALSE,"7,041",TEST,HY
28,3244,2972614,Motion range - Shoulder internal rotation,Laser therapy (Group I),Placebo laser therapy (Group II),no significant difference,0,continuous,,30,,22,49.33,9.62,49.77,4.49,-0.055,0.0788,,,,,Outcome originally just Motion range.,FALSE,TRUE,FALSE,FALSE,"7,041",TEST,HY
29,3244,2972614,Motion range - Shoulder external rotation,Laser therapy (Group I),Placebo laser therapy (Group II),no significant difference,0,continuous,,30,,22,44.83,5.64,44.09,1.97,0.1626,0.079,,,,,Outcome originally just Motion range.,FALSE,TRUE,FALSE,FALSE,"7,041",TEST,HY
30,5576,3003523,Short-Form 36-Items improvement,Certolizumab 200 mg,Control,significantly increased,1,continuous,,393,,199,38.1,9.5,31.5,7.4,0.7447,0.008,,,,,Used values for PCS after 52 weeks (final timepoint).,FALSE,TRUE,FALSE,TRUE,"12,247",TEST,HY
31,5577,3003523,Short-Form 36-Items improvement,Certolizumab 400 mg,Control,significantly increased,1,continuous,,390,,199,38.9,8.9,31.5,7.4,0.8773,0.0082,,,,,Used values for PCS after 52 weeks (final timepoint).,FALSE,TRUE,FALSE,TRUE,"12,247",TEST,HY
32,5580,3003523,Pain,Certolizumab 400 mg,Control,significantly decreased,-1,continuous,,390,,199,53.9,22.2,34,20.1,0.9238,0.0083,,,,,Used values for weeks 52 (final timepoint).,FALSE,TRUE,FALSE,TRUE,"12,247",TEST,HY
33,5575,3003523,Health-related quality of life improvement - Short-Form 36-Items improvement,Certolizumab 200 mg,Control,significantly increased,1,continuous,,393,,199,38.1,9.5,31.5,7.4,0.7447,0.008,,,,,This outcome is measured by Short-Form 36-Items (SF-36).,FALSE,FALSE,FALSE,FALSE,"12,247",TEST,HY
34,5578,3003523,Mental Component Summary improvement,Certolizumab 400 mg,Control,significantly increased,1,continuous,,390,,199,45.4,11.5,41.1,10.8,0.3811,0.0077,,,,,Used values for MCS after 52 weeks (final timepoint).,FALSE,TRUE,FALSE,TRUE,"12,247",TEST,HY
35,5579,3003523,Fatigue Assessment Scale improvement,Certolizumab 200 mg,Control,significantly increased,1,continuous,,393,,199,,,,,cannot calculate,cannot calculate,,,,,Values are in figure.,TRUE,FALSE,FALSE,FALSE,"12,247",TEST,HY
36,6988,3169777,adverse event profile - headache,macitentan dose of 600 mg,placebo,significantly increased,1,binary,5,6,3,14,,,,,,,2.9087,1.6242,1.3581,0.2952,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,"5,143",TEST,HY
37,6985,3169777,unexpected adverse events,macitentan doses of 0.2 mg,placebo,no significant difference,0,binary,0,6,0,14,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,"5,143",TEST,HY
38,6985,3169777,unexpected adverse events,macitentan doses of 1 mg,placebo,no significant difference,0,binary,0,6,0,14,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,"5,143",TEST,HY
39,6985,3169777,unexpected adverse events,macitentan doses of 5 mg,placebo,no significant difference,0,binary,0,6,0,14,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,"5,143",TEST,HY
40,6985,3169777,unexpected adverse events,macitentan doses of 25 mg,placebo,no significant difference,0,binary,0,6,0,14,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,"5,143",TEST,HY
41,6985,3169777,unexpected adverse events,macitentan doses of 100 mg,placebo,no significant difference,0,binary,0,6,0,14,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,"5,143",TEST,HY
42,6985,3169777,unexpected adverse events,macitentan doses of 300 mg,placebo,no significant difference,0,binary,0,6,0,14,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,"5,143",TEST,HY
43,6985,3169777,unexpected adverse events,macitentan doses of 600 mg,placebo,no significant difference,0,binary,0,6,0,14,,,,,,,0.8023,4.2228,0.7621,3.7905,One sentence that said no unexpected adverse events were found so values are all 0 based on this.,FALSE,FALSE,FALSE,TRUE,"5,143",TEST,HY
44,6986,3169777,Plasma endothelin-1 concentrations,macitentan dose of 600 mg,placebo,significantly increased,1,continuous,,6,,14,,,,,cannot calculate,cannot calculate,,,,,The mean and SD are in bar chart (figure),TRUE,FALSE,FALSE,FALSE,"5,143",TEST,HY
45,6989,3169777,adverse event profile - headache,macitentan doses of 0.2 mg,placebo,no significant difference,0,binary,0,6,3,14,,,,,,,-1.3754,2.5265,-1.1838,2.0762,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,"5,143",TEST,HY
46,6989,3169777,adverse event profile - headache,macitentan doses of 1 mg,placebo,no significant difference,0,binary,0,6,3,14,,,,,,,-1.3754,2.5265,-1.1838,2.0762,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,"5,143",TEST,HY
47,6989,3169777,adverse event profile - headache,macitentan doses of 5 mg,placebo,no significant difference,0,binary,0,6,3,14,,,,,,,-1.3754,2.5265,-1.1838,2.0762,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,"5,143",TEST,HY
48,6989,3169777,adverse event profile - headache,macitentan doses of 25 mg,placebo,no significant difference,0,binary,2,6,3,14,,,,,,,0.6061,1.1742,0.4418,0.5952,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,"5,143",TEST,HY
49,6989,3169777,adverse event profile - headache,macitentan doses of 100 mg,placebo,no significant difference,0,binary,1,6,3,14,,,,,,,-0.3102,1.6242,-0.2513,1.0952,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,"5,143",TEST,HY
50,6989,3169777,adverse event profile - headache,macitentan doses of 300 mg,placebo,no significant difference,0,binary,2,6,3,14,,,,,,,0.6061,1.1742,0.4418,0.5952,"Original outcome was ""adverse events profile"". Added ""headeache"" since that is the first adverse events reported.",FALSE,TRUE,FALSE,TRUE,"5,143",TEST,HY
51,5308,3195393,Continuous restraint,After restraint reduction program,Before restraint reduction program,significantly decreased,-1,continuous,,562,,463,8.5,0.07,10.8,0.13,-19.6737,0.1927,,,,,Overall continuous restraint rate for study site.,FALSE,TRUE,FALSE,TRUE,"15,527",TEST,HY
52,5306,3195393,Restraint frecuency,After restraint reduction program,Before restraint reduction program,no significant difference,0,continuous,,562,,463,13.6,0.07,11.5,0.13,20.6573,0.2121,,,,,Added intermittent and continuous numbers from study site,FALSE,TRUE,FALSE,TRUE,"15,527",TEST,HY
53,5307,3195393,Intermittent restraint,After restraint reduction program,Before restraint reduction program,significantly increased,1,continuous,,562,,463,5.1,0.07,0.7,0.02,9.6931,0.0498,,,,,Overall intermittent restraint rate for study site.,FALSE,TRUE,FALSE,TRUE,"15,527",TEST,HY
54,5309,3195393,Restraint knowledge,After restraint reduction program,Before restraint reduction program,significantly increased,1,continuous,,562,,463,6.23,,5.51,,cannot calculate,cannot calculate,,,,,No SD information provided,FALSE,FALSE,FALSE,FALSE,"15,527",TEST,HY
55,10673,3276927,relieving factors in reversible inguinal hernia,post-Yoga,pre-Yoga,significantly increased,1,continuous,,19,,19,,,,,cannot calculate,cannot calculate,,,,,Data found in table in graphic format.,FALSE,TRUE,TRUE,FALSE,"2,011",DEV,HY
56,10676,3276927,effective in the treatment of reversible inguinal hernia,post-Yoga,pre-Yoga,significantly increased,1,binary,,19,,19,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,"No real numerical data attached to this specific outcome. Other prompts account for ""treatment""",FALSE,FALSE,TRUE,FALSE,"2,011",DEV,HY
57,10672,3276927,frequency of occurrence in reversible inguinal hernia,post-Yoga,pre-Yoga,significantly decreased,-1,continuous,,19,,19,,,,,cannot calculate,cannot calculate,,,,,Only median and range is given.,FALSE,TRUE,TRUE,FALSE,"2,011",DEV,HY
58,10671,3276927,"symptoms of hernia such as heaviness, fullness and pain",post-Yoga,pre-Yoga,significantly decreased,-1,continuous,,19,,19,,,,,cannot calculate,cannot calculate,,,,,No specific numerical data associated with these symptoms.,FALSE,FALSE,TRUE,FALSE,"2,011",DEV,HY
59,10674,3276927,pain in reversible inguinal hernia,post-Yoga,pre-Yoga,significantly decreased,-1,continuous,,19,,19,,,,,cannot calculate,cannot calculate,,,,,Only median and range is given.,FALSE,TRUE,TRUE,FALSE,"2,011",DEV,HY
60,10675,3276927,aggravating factors in reversible inguinal hernia,post-Yoga,pre-Yoga,significantly decreased,-1,continuous,,19,,19,,,,,cannot calculate,cannot calculate,,,,,Only median and range is given.,FALSE,TRUE,TRUE,FALSE,"2,011",DEV,HY
61,1642,3309311,differences in the disc herniation,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",significantly increased,1,binary,,23,,19,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Data is in graphic table.,FALSE,TRUE,TRUE,TRUE,"1,437",TEST,HY
62,1642,3309311,differences in the HDD,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",significantly increased,1,binary,,23,,19,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Data is in graphic table.,FALSE,TRUE,TRUE,TRUE,"1,437",TEST,HY
63,1642,3309311,differences in the annulus tear,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",significantly increased,1,binary,,23,,19,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Data is in graphic table.,FALSE,TRUE,TRUE,TRUE,"1,437",TEST,HY
64,1642,3309311,differences in the HIZ,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",significantly increased,1,binary,,23,,19,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Data is in graphic table.,FALSE,TRUE,TRUE,TRUE,"1,437",TEST,HY
65,1644,3309311,The proportion of HIZ incidence,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)",adults with LBP with radicular pain (group C),significantly increased,1,binary,14,23,3,18,,,,,,,2.0513,0.5825,1.2953,0.3057,Used percentage to calculate events as binary outcome.,FALSE,FALSE,TRUE,TRUE,"1,437",TEST,HY
66,1643,3309311,The proportion of HIZ incidence,"adults with acute axial severe LBP who could not sit up or stand up for several days, but had not experienced previous back-related diseases or trauma (group A)","adults who had been involved in a minor traffic accident, and had mild symptoms but not limited mobility (group B)",significantly increased,1,binary,14,23,4,19,,,,,,,1.7636,0.4992,1.0617,0.2253,Used percentage to calculate events as binary outcome.,FALSE,FALSE,TRUE,TRUE,"1,437",TEST,HY
67,3041,3321528,wrist flexion,electrical muscle stimulation (EMS),control,significantly increased,1,continuous,,24,,28,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,FALSE,TRUE,FALSE,FALSE,"6,725",TEST,HY
68,3041,3321528,hip flexion,electrical muscle stimulation (EMS),control,significantly increased,1,continuous,,24,,28,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,FALSE,TRUE,FALSE,FALSE,"6,725",TEST,HY
69,3041,3321528,knee extension,electrical muscle stimulation (EMS),control,significantly increased,1,continuous,,24,,28,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,FALSE,TRUE,FALSE,FALSE,"6,725",TEST,HY
70,3041,3321528,ankle dorsiflexion,electrical muscle stimulation (EMS),control,significantly increased,1,continuous,,24,,28,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,FALSE,TRUE,FALSE,FALSE,"6,725",TEST,HY
71,3043,3321528,handgrip strength,Intensive Care Unit acquired weakness (ICU-AW),without an ICU-AW diagnosis,significantly decreased,-1,continuous,,,,,6.6,4.4,23.4,8.9,cannot calculate,cannot calculate,,,,,Does not have group size information in article.,FALSE,FALSE,FALSE,FALSE,"6,725",TEST,HY
72,3042,3321528,the total MRC score of the legs,electrical muscle stimulation (EMS),control,significantly increased,1,continuous,,24,,28,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,FALSE,FALSE,FALSE,FALSE,"6,725",TEST,HY
73,3741,3546023,Urine cotinine levels,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,significantly increased,1,continuous,,30,,19,1.179,0.738,0.047,0.017,2.0036,0.1541,,,,,Values are for week 24 (only timepoint after intervention).,FALSE,TRUE,FALSE,TRUE,"29,733",TEST,HY
74,3742,3546023,serum α1-antitrypsin,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,significantly increased,1,continuous,,30,,19,1.75,0.39,1.45,0.24,0.867,0.0936,,,,,Values are for week 24 (only timepoint after intervention).,FALSE,TRUE,FALSE,TRUE,"29,733",TEST,HY
75,3743,3546023,The percentage of B cells,200 mg/day palmvitee nonsmokers,baseline,significantly increased,1,continuous,,29,,29,11.97,4,13.72,4.53,-0.404,0.0704,,,,,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,"29,733",TEST,HY
76,3744,3546023,The percentage of B cells,200 mg/day palmvitee smokers,baseline,no significant difference,0,continuous,,30,,30,14.06,3.81,14.4,4.03,-0.0856,0.0667,,,,,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,"29,733",TEST,HY
77,3746,3546023,The percentage of NK cells,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,significantly decreased,-1,continuous,,30,,29,19.03,7.82,24.72,8.78,-0.6721,0.0716,,,,,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,"29,733",TEST,HY
78,3740,3546023,tocopherol levels,200 mg/day palmvitee smokers,baseline,significantly increased,1,continuous,,30,,30,14.11,3.89,11.39,3.06,0.7671,0.0716,,,,,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,"29,733",TEST,HY
79,3740,3546023,tocotrienol levels,200 mg/day palmvitee smokers,baseline,significantly increased,1,continuous,,30,,30,587.68,87.5,59.49,4.21,8.4162,0.6569,,,,,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,"29,733",TEST,HY
80,3740,3546023,tocopherol levels,200 mg/day palmvitee nonsmokers,baseline,significantly increased,1,continuous,,29,,29,14.56,3.06,11.75,2.27,1.029,0.0781,,,,,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,"29,733",TEST,HY
81,3740,3546023,tocotrienol levels,200 mg/day palmvitee nonsmokers,baseline,significantly increased,1,continuous,,29,,29,675.16,150,63.6,5.67,5.6842,0.3475,,,,,Values are between baseline and week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,"29,733",TEST,HY
82,3745,3546023,CD4+/CD8+ ratio,200 mg/day palmvitee smokers,200 mg/day palmvitee nonsmokers,significantly increased,1,continuous,,30,,29,1.19,0.43,1.03,0.53,0.3277,0.0687,,,,,Values are for week 24 (final timepoint).,FALSE,TRUE,FALSE,TRUE,"29,733",TEST,HY
83,11789,3580751,mean ± SD length of hospital stay between periods 1 and 2 in patients who did not suffer from VAP,Interrupted surveillance unit A,"Continuous surveillance, unit B",significantly increased,1,continuous,,940,,1831,9.9,14.8,9.1,9.9,0.0678,0.0016,,,,,Values are from post-intervention.,FALSE,FALSE,FALSE,TRUE,"5,335",DEV,HY
84,13566,3687098,adverse event of constipation,sitagliptin 100 mg/day,comparator agent,significantly increased,1,binary,178,7726,124,6885,,,,,,,0.2514,0.014,0.2463,0.0134,Used incidence rate per 100 to get the binary events.,FALSE,TRUE,FALSE,TRUE,"15,196",TEST,HY
85,13567,3687098,The incidence rates of malignancy,sitagliptin 100 mg/day,comparator agent,no significant difference,0,binary,6953,7726,6403,6885,,,,,,,-0.3899,0.0037,-0.0328,0,Used incidence rate per 100 to get the binary events.,FALSE,FALSE,FALSE,TRUE,"15,196",TEST,HY
86,13568,3687098,The incidence rates of pancreatitis,sitagliptin 100 mg/day,comparator agent,no significant difference,0,binary,773,7726,689,6885,,,,,,,-0.0002,0.0031,-0.0002,0.0025,Used incidence rate per 100 to get the binary events.,FALSE,TRUE,FALSE,TRUE,"15,196",TEST,HY
87,13569,3687098,The incidence of the composite endpoint of rash,sitagliptin 100 mg/day,comparator agent,significantly increased,1,binary,131,7726,76,6885,,,,,,,0.4352,0.0211,0.4292,0.0205,Used incidence rate per 100 to get the binary events.,FALSE,TRUE,FALSE,TRUE,"15,196",TEST,HY
88,13244,3751573,improvement in nursing,phase I externship program,phase II corporate-academic cooperation program,significantly increased,1,continuous,,19,,23,117.63,19.01,158.52,23.19,-1.8738,0.1379,,,,,Used post-intervention values.,FALSE,TRUE,FALSE,TRUE,"8,149",DEV,HY
89,5538,3912320,Correct response rate for 500 Hz frequency,Occupational noise,Control,significantly decreased,-1,continuous,,19,,10,,,,,cannot calculate,cannot calculate,,,,,Mean were in a figure and SD was not given anywhere.,TRUE,FALSE,FALSE,FALSE,"1,648",TEST,HY
90,5540,3912320,"Correct response rate for 4,000 Hz frequency",Occupational noise,Control,significantly decreased,-1,continuous,,19,,10,,,,,cannot calculate,cannot calculate,,,,,Mean were in a figure and SD was not given anywhere.,TRUE,FALSE,FALSE,FALSE,"1,648",TEST,HY
91,5539,3912320,"Correct response rate for 2,000 Hz frequency",Occupational noise,Control,significantly decreased,-1,continuous,,19,,10,,,,,cannot calculate,cannot calculate,,,,,Mean were in a figure and SD was not given anywhere.,TRUE,FALSE,FALSE,FALSE,"1,648",TEST,HY
92,10164,4173437,Postoperatively hematocrit,Tranexamic acid,Control,significantly increased,1,continuous,,30,,30,,,,,cannot calculate,cannot calculate,,,,,Had to infer that the group sizes were equal. Data is in table in graphic format.,FALSE,TRUE,TRUE,FALSE,854,TEST,HY
93,10166,4173437,Complications,Tranexamic acid,Control,no significant difference,0,binary,0,30,0,30,,,,,,,0,4.0656,0,3.9355,Had to infer that the group sizes were equal.,FALSE,FALSE,TRUE,TRUE,854,TEST,HY
94,10167,4173437,Adverse effects,Tranexamic acid,Control,no significant difference,0,binary,0,30,0,30,,,,,,,0,4.0656,0,3.9355,Had to infer that the group sizes were equal.,FALSE,FALSE,TRUE,TRUE,854,TEST,HY
95,10163,4173437,Total blood loss,Tranexamic acid,Control,significantly decreased,-1,continuous,,30,,30,576,53,823,74,-3.7878,0.1862,,,,,Had to infer that the group sizes were equal.,FALSE,FALSE,TRUE,TRUE,854,TEST,HY
96,10165,4173437,Coagulation profile,Tranexamic acid,Control,no significant difference,0,continuous,,30,,30,,,,,cannot calculate,cannot calculate,,,,,Had to infer that the group sizes were equal. Data is in table in graphic format.,FALSE,TRUE,TRUE,FALSE,854,TEST,HY
97,10168,4173437,Crystalloid solution needed,Tranexamic acid,Control,no significant difference,0,continuous,,30,,30,,,,,cannot calculate,cannot calculate,,,,,Had to infer that the group sizes were equal. No numerical values associated with this outcome.,FALSE,FALSE,TRUE,FALSE,854,TEST,HY
98,931,4183415,completion of each dose at the correct time,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,no significant difference,0,continuous,,40,,37,33.1,21.6,32.6,18.4,0.0246,0.052,,,,,Data found in Table 6.,FALSE,TRUE,FALSE,TRUE,"10,420",TEST,HY
99,929,4183415,patient adherence,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,no significant difference,0,continuous,,40,,37,68.3,23.4,69.8,20.9,-0.0668,0.0521,,,,,"Data found in Table 6. Used same values as ""completed treatment""",FALSE,TRUE,FALSE,TRUE,"10,420",TEST,HY
100,930,4183415,Completed treatment,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,no significant difference,0,continuous,,40,,37,68.3,23.4,69.8,20.9,-0.0668,0.0521,,,,,Data found in Table 6.,FALSE,TRUE,FALSE,TRUE,"10,420",TEST,HY
101,1886,4188762,heart rate,remifentanil,normal saline,significantly decreased,-1,continuous,,30,,30,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,TRUE,FALSE,"2,068",TEST,HY
102,1886,4188762,heart rate,remifentanil,lidocaine,significantly decreased,-1,continuous,,30,,30,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,TRUE,FALSE,"2,068",TEST,HY
103,1886,4188762,heart rate,remifentanil,ketamine,significantly decreased,-1,continuous,,30,,30,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,TRUE,FALSE,"2,068",TEST,HY
104,1885,4188762,mean blood pressure,remifentanil,normal saline,significantly decreased,-1,continuous,,30,,30,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,TRUE,FALSE,"2,068",TEST,HY
105,1885,4188762,mean blood pressure,remifentanil,lidocaine,significantly decreased,-1,continuous,,30,,30,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,TRUE,FALSE,"2,068",TEST,HY
106,1885,4188762,mean blood pressure,remifentanil,"normal saline, lidocaine, or ketamine",significantly decreased,-1,continuous,,30,,30,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,TRUE,FALSE,"2,068",TEST,HY
107,1884,4188762,withdrawal response of rocuronium,lidocaine,normal saline,significantly decreased,-1,binary,6,30,26,30,,,,,,,-3.2581,0.4968,-1.4663,0.1385,Used percentage to calculate events as binary outcome.,FALSE,FALSE,TRUE,TRUE,"2,068",TEST,HY
108,1884,4188762,withdrawal response of rocuronium,ketamine,normal saline,significantly decreased,-1,binary,9,30,26,30,,,,,,,-2.7191,0.4472,-1.0609,0.0829,Used percentage to calculate events as binary outcome.,FALSE,FALSE,TRUE,TRUE,"2,068",TEST,HY
109,1884,4188762,withdrawal response of rocuronium,remifentanil,normal saline,significantly decreased,-1,binary,0,30,26,30,,,,,,,-5.8839,2.2927,-3.9703,1.9732,Used percentage to calculate events as binary outcome.,FALSE,FALSE,TRUE,TRUE,"2,068",TEST,HY
110,9521,4319071,High-energy snack intake,Individual cognition and self-regulation processes intervention,Control,significantly decreased,-1,continuous,,459,,434,2.5,2.79,2.84,2.71,-0.1235,0.0045,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,"26,475",TEST,HY
111,9522,4319071,High-energy snack intake,Intervention + targeting environmental-level factors,Control,significantly decreased,-1,continuous,,456,,434,2.5,2.76,2.84,2.71,-0.1242,0.0045,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,"26,475",TEST,HY
112,9525,4319071,Vegetable intake,Intervention + targeting environmental-level factors,Control,no significant difference,0,continuous,,456,,434,167.61,83.71,158.67,78.33,0.1101,0.0045,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,"26,475",TEST,HY
113,9526,4319071,Vegetable intake,Intervention + targeting environmental-level factors,Individual cognition and self-regulation processes intervention,no significant difference,0,continuous,,456,,459,167.61,83.71,173.28,81.63,-0.0685,0.0044,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,"26,475",TEST,HY
114,9523,4319071,Fruit intake,Intervention + targeting environmental-level factors,Control,significantly increased,1,continuous,,456,,434,2.17,1.71,2,1.67,0.1005,0.0045,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,"26,475",TEST,HY
115,9524,4319071,Fruit intake,Intervention + targeting environmental-level factors,Individual cognition and self-regulation processes intervention,significantly increased,1,continuous,,456,,459,2.17,1.71,2.14,1.71,0.0175,0.0044,,,,,Values are from 4-month follow up (final timepoint). Back calculated the SD values from SE.,FALSE,TRUE,FALSE,TRUE,"26,475",TEST,HY
116,2982,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Deep-cooling,Mild-cooling,no significant difference,0,continuous,,9,,10,,,70,,cannot calculate,cannot calculate,,,,,,FALSE,TRUE,TRUE,FALSE,"3,049",TEST,HY
117,2983,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Deep-cooling,No cooling,no significant difference,0,continuous,,9,,13,,,15.4,,cannot calculate,cannot calculate,,,,,,FALSE,TRUE,TRUE,FALSE,"3,049",TEST,HY
118,2984,4323894,Rate of complications,Mild-cooling or deep-cooling,No cooling,no significant difference,0,binary,,10,,13,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,,FALSE,TRUE,TRUE,FALSE,"3,049",TEST,HY
119,2981,4323894,Improvement in Glasgow outcome score at 6 months post-trauma,Mild-cooling,No cooling,significantly increased,1,continuous,,10,,13,70,,15.4,,cannot calculate,cannot calculate,,,,,,FALSE,TRUE,TRUE,FALSE,"3,049",TEST,HY
120,3102,4450164,ureteropelvic junction obstruction,internal drainage group,stentless cases,no significant difference,0,binary,8,20,13,44,,,,,,,0.4636,0.3175,0.3029,0.1292,,FALSE,TRUE,FALSE,TRUE,"3,862",DEV,HY
121,7938,4486927,"The SVR rates if the patients had IL-28B rs8099917 TT genotype, and GT/GG genotype",peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,significantly increased,1,binary,17,23,2,24,,,,,,,3.4393,0.7709,2.1826,0.4737,"Even though the outcome says rate, the way that the results are reported in the table makes it easier to calculate as binary outcome.",FALSE,TRUE,FALSE,TRUE,"14,472",TEST,HY
122,7936,4486927,The early virologic response (EVR),peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,no significant difference,0,binary,86,94,82,93,,,,,,,0.3661,0.2397,0.0369,0.0024,,FALSE,TRUE,FALSE,TRUE,"14,472",TEST,HY
123,7936,4486927,the end-of-treatment virologic response,peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,no significant difference,0,binary,83,94,75,93,,,,,,,0.5938,0.1718,0.0907,0.004,,FALSE,TRUE,FALSE,TRUE,"14,472",TEST,HY
124,7937,4486927,The SVR rates when the patients had BMI >30 kg/m2,peginterferon (Peg-IFN) plus ribavirin (RBV) for 48 weeks,peginterferon (Peg-IFN) plus ribavirin (RBV) for 24 weeks,no significant difference,0,binary,10,19,6,12,,,,,,,0.1054,0.5444,0.0513,0.1307,"Even though the outcome says rate, the way that the results are reported in the table makes it easier to calculate as binary outcome.",FALSE,TRUE,FALSE,TRUE,"14,472",TEST,HY
125,4926,4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,and H2 (haloperidol 2 mg),H0 (saline),significantly increased,1,continuous,,50,,50,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,"3,932",TEST,HY
126,4926,4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,and H2 (haloperidol 2 mg),H1(haloperidol 1 mg),significantly increased,1,continuous,,50,,49,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,"3,932",TEST,HY
127,4924,4493951,the incidence of postoperative nausea and vomiting (PONV),H1(haloperidol 1 mg),H0 (saline),significantly decreased,-1,binary,11,49,21,50,,,,,,,-0.9169,0.1993,-0.6264,0.0981,Used numbers from Late time (2–24 h),FALSE,TRUE,FALSE,TRUE,"3,932",TEST,HY
128,4924,4493951,the incidence of postoperative nausea and vomiting (PONV),H2 (haloperidol 2 mg),H0 (saline),significantly decreased,-1,binary,10,50,21,50,,,,,,,-1.0635,0.2071,-0.7419,0.1076,Used numbers from Late time (2–24 h),FALSE,TRUE,FALSE,TRUE,"3,932",TEST,HY
129,4927,4493951,The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period,H0 (saline),"H1(haloperidol 1 mg),",no significant difference,0,continuous,,50,,49,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,"3,932",TEST,HY
130,4925,4493951,the incidence of postoperative nausea and vomiting (PONV),H1(haloperidol 1 mg),H2 (haloperidol 2 mg),no significant difference,0,binary,11,49,10,50,,,,,,,0.1466,0.2422,0.1155,0.1505,Used numbers from Late time (2–24 h),FALSE,TRUE,FALSE,TRUE,"3,932",TEST,HY
131,2451,4574984,numbers overall complications,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",no significant difference,0,binary,238,326,241,326,,,,,,,-0.0472,0.0315,-0.0125,0.0022,,FALSE,TRUE,FALSE,TRUE,"12,997",TEST,HY
132,2452,4574984,level of postoperative pain,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",significantly decreased,-1,binary,234,326,261,326,,,,,,,-0.4566,0.0344,-0.1092,0.002,,FALSE,TRUE,FALSE,TRUE,"12,997",TEST,HY
133,2453,4574984,overall mortality,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",no significant difference,0,binary,45,326,58,326,,,,,,,-0.3011,0.0468,-0.2538,0.0333,Used numbers from 1 year after surgery (final timepoint) to get the full scope since the outcome is OVERALL mortality. This info is found in Figure 6 caption.,FALSE,FALSE,FALSE,TRUE,"12,997",TEST,HY
134,2449,4574984,Health-Related Quality of Life at 12 month - females,"intervention group, i.e. patient empowerment through information booklet and diary keeping - females","control group, which received standard care - females",no significant difference,0,continuous,,110,,95,61.07,30.21,63.27,24.79,-0.0788,0.0196,,,,,Group sizes was inferred using Table of characterisitics. Back calculated SD using CI.,FALSE,FALSE,FALSE,FALSE,"12,997",TEST,HY
135,2450,4574984,Health-Related Quality of Life at 12 month - males,"intervention group, i.e. patient empowerment through information booklet and diary keeping - males","control group, which received standard care - males",no significant difference,0,continuous,,216,,231,72.49,23.66,71.71,27.1,0.0305,0.009,,,,,Group sizes was inferred using Table of characterisitics. Back calculated SD using CI.,FALSE,FALSE,FALSE,FALSE,"12,997",TEST,HY
136,2448,4574984,postoperative in-hospital stay,"intervention group, i.e. patient empowerment through information booklet and diary keeping","control group, which received standard care",no significant difference,0,continuous,,326,,326,,,,,cannot calculate,cannot calculate,,,,,Only median and interquartile range is given.,FALSE,FALSE,FALSE,FALSE,"12,997",TEST,HY
137,1267,4709985,would have liked more information on acupuncture,tertiary education,other educations,significantly increased,1,binary,,121,,89,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Specific numbers were not given.,FALSE,FALSE,FALSE,FALSE,"3,939",TEST,HY
138,3101,4830045,Birth status,Patients in the 3h group,Patients in the 20h group,no significant difference,0,binary,32,74,22,60,,,,,,,1 0.2746,0.1268,0.165,0.0465,Used numbers for live birth rate.,FALSE,TRUE,FALSE,TRUE,"2,530",TEST,HY
139,3100,4830045,Embryo quality,Patients in the 3h group,Patients in the 20h group,significantly increased,1,binary,,74,,60,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Unclear outcome measures.,FALSE,FALSE,FALSE,FALSE,"2,530",TEST,HY
140,1275,4880652,SpO2 at 5 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,significantly decreased,-1,continuous,,76,,70,,,,,cannot calculate,cannot calculate,,,,,Mean in figure 5's graphics.,TRUE,FALSE,TRUE,FALSE,"1,406",TEST,HY
141,1272,4880652,the modified Aldrete scores at 60 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,no significant difference,0,continuous,,76,,70,,,,,cannot calculate,cannot calculate,,,,,Mean and SD are in table that is in graphic form.,FALSE,TRUE,TRUE,FALSE,"1,406",TEST,HY
142,1272,4880652,systolic pressures at 0 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,no significant difference,0,continuous,,76,,70,,,,,cannot calculate,cannot calculate,,,,,Mean in figure 3's graphics.,TRUE,FALSE,TRUE,FALSE,"1,406",TEST,HY
143,1272,4880652,"oxygen saturation at 10, 15, 20 minutes",fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,no significant difference,0,continuous,,76,,70,,,,,cannot calculate,cannot calculate,,,,,Means in figure 5's graphics.,TRUE,FALSE,TRUE,FALSE,"1,406",TEST,HY
144,1272,4880652,"diastolic blood pressure at 10, 15, 20 minutes",fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,no significant difference,0,continuous,,76,,70,,,,,cannot calculate,cannot calculate,,,,,Means in figure 4's graphics.,TRUE,FALSE,TRUE,FALSE,"1,406",TEST,HY
145,1272,4880652,heart rates,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,no significant difference,0,continuous,,76,,70,,,,,cannot calculate,cannot calculate,,,,,Means in figure 2's graphics.,TRUE,FALSE,TRUE,FALSE,"1,406",TEST,HY
146,1272,4880652,visual analogue scores,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,no significant difference,0,continuous,,76,,70,,,,,cannot calculate,cannot calculate,,,,,Mean and SD are in table that is in graphic form.,FALSE,TRUE,TRUE,FALSE,"1,406",TEST,HY
147,1273,4880652,"systolic blood pressures at 5, 10, 15, and 20 minutes",fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,significantly decreased,-1,continuous,,76,,70,,,,,cannot calculate,cannot calculate,,,,,Means in figure 3's graphics.,TRUE,FALSE,TRUE,FALSE,"1,406",TEST,HY
148,1274,4880652,Diastolic blood pressures at 5 minutes,fentanyl (1 µg/kg) and propofol,paracetamol (20 mg/kg) and propofol,significantly decreased,-1,continuous,,76,,70,,,,,cannot calculate,cannot calculate,,,,,Mean in figure 4's graphics.,TRUE,FALSE,TRUE,FALSE,"1,406",TEST,HY
149,11146,4996097,"""a"" vowel improvement",Septoplasty,Control,no significant difference,0,continuous,,33,,30,138,,154,,cannot calculate,cannot calculate,,,,,Used F0 (Hz) values. SD is not given.,FALSE,TRUE,FALSE,FALSE,"9,291",TEST,HY
150,11145,4996097,Total nasal resistance,Septoplasty,Control,no significant difference,0,continuous,,33,,30,0.25,,0.27,,cannot calculate,cannot calculate,,,,,Used preoperative values. SD is not given.,FALSE,TRUE,FALSE,FALSE,"9,291",TEST,HY
151,11147,4996097,"""n"" consonant improvement",Septoplasty,Control,significantly increased,1,continuous,,33,,30,11897,,13229,,cannot calculate,cannot calculate,,,,,Used F0 (Hz) values. SD is not given.,FALSE,TRUE,FALSE,FALSE,"9,291",TEST,HY
152,13479,5055753,The percentages of patients in the calm,0.2 mg oral clonidine,2 mg oral midazolam,significantly increased,1,binary,14,40,7,40,,,,,,,0.9316,0.2831,0.6931,0.1643,"Even though the outcome says percentage, the way that the results are reported in the table makes it easier to calculate as binary outcome.",FALSE,FALSE,FALSE,TRUE,"3,292",TEST,HY
153,13479,5055753,The percentages of patients in the sedated scale,0.2 mg oral clonidine,2 mg oral midazolam,significantly increased,1,binary,17,40,7,40,,,,,,,1.2483,0.2755,0.8873,0.1517,"Even though the outcome says percentage, the way that the results are reported in the table makes it easier to calculate as binary outcome.",FALSE,FALSE,FALSE,TRUE,"3,292",TEST,HY
154,13480,5055753,the percentages of patients in the agitated sedation scale,0.2 mg oral clonidine,2 mg oral midazolam,significantly decreased,-1,binary,,40,,40,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,,TRUE,FALSE,FALSE,FALSE,"3,292",TEST,HY
155,13480,5055753,the percentages of patients in the heavily sedated,0.2 mg oral clonidine,2 mg oral midazolam,significantly decreased,-1,binary,,40,,40,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,,TRUE,FALSE,FALSE,FALSE,"3,292",TEST,HY
156,13481,5055753,The mean ¬± SD of intraoperatively administered fentany,0.2 mg oral clonidine,2 mg oral midazolam,significantly decreased,-1,continuous,,40,,40,105,30.8,165,34.5,-1.817,0.0706,,,,,,FALSE,FALSE,FALSE,TRUE,"3,292",TEST,HY
157,13482,5055753,Mean ± SD of heart rate,0.2 mg oral clonidine,2 mg oral midazolam,no significant difference,0,continuous,,40,,40,,,,,cannot calculate,cannot calculate,,,,,Info in figure graphics.,TRUE,FALSE,FALSE,FALSE,"3,292",TEST,HY
158,7710,5056957,Weight reduction at 12 months,Multi-component physical activity,Usual PE and sport programmes,significantly increased,1,continuous,,592,,459,55.91,15.64,56.48,14.76,-0.0373,0.0039,,,,,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,"11,185",TEST,HY
159,7710,5056957,BMI reduction at 12 months,Multi-component physical activity,Usual PE and sport programmes,significantly increased,1,continuous,,592,,459,21.07,6.39,21.27,5.9,-0.0323,0.0039,,,,,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,"11,185",TEST,HY
160,7711,5056957,BMI z-score at 12months,Multi-component physical activity,Usual PE and sport programmes,no significant difference,0,continuous,,592,,459,0.61,1.8,0.66,1.69,-0.0285,0.0039,,,,,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,"11,185",TEST,HY
161,7712,5056957,Weight reduction at 24 months,Multi-component physical activity,Usual PE and sport programmes,significantly increased,1,continuous,,560,,425,61.08,15.15,61.94,14.25,-0.0582,0.0041,,,,,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,"11,185",TEST,HY
162,7712,5056957,BMI reduction at 24 months,Multi-component physical activity,Usual PE and sport programmes,significantly increased,1,continuous,,560,,425,21.86,6.22,22.06,5.68,-0.0333,0.0041,,,,,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,"11,185",TEST,HY
163,7713,5056957,BMI z-score at 24 months,Multi-component physical activity,Usual PE and sport programmes,significantly decreased,-1,continuous,,560,,425,0.69,1.81,0.71,1.63,-0.0115,0.0041,,,,,Back calculated the SD values from CI,FALSE,TRUE,FALSE,TRUE,"11,185",TEST,HY
164,617,5062234,The visual analog scale scores at rest and on coughing,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,significantly decreased,-1,continuous,,21,,21,,,,,cannot calculate,cannot calculate,,,,,Data found in table in graphic format.,FALSE,TRUE,TRUE,FALSE,"1,345",TEST,HY
165,615,5062234,The 24 h morphine requirement,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,no significant difference,0,continuous,,21,,21,34.57,14.64,32.76,14.34,0.1225,0.0954,,,,,,FALSE,FALSE,TRUE,TRUE,"1,345",TEST,HY
166,616,5062234,intraoperative supplemental fentanyl,Transversus abdominis plane block with 0.375% ropivacaine,local anesthetic infiltration of the port site.,significantly decreased,-1,binary,8,21,16,21,,,,,,,-1.6487,0.4644,-0.6931,0.0923,,FALSE,FALSE,TRUE,TRUE,"1,345",TEST,HY
167,2797,5079604,Disposition index (DI),subjects who remained in remission,patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si),significantly increased,1,continuous,,28,,20,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,"12,690",TEST,HY
168,2797,5079604,incremental area under the curve for insulin (AUCi),subjects who remained in remission,patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si),significantly increased,1,continuous,,28,,20,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,"12,690",TEST,HY
169,2792,5079604,hyperglycemia relapse-free survival,"metformin 1,000 mg daily",sitagliptin 100 mg daily,no significant difference,0,continuous,,17,,16,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,"12,690",TEST,HY
170,2795,5079604,Cox proportional hazards of failure-free survival,"metformin 1,000 mg daily",sitagliptin 100 mg daily,no significant difference,0,continuous,,17,,16,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,"12,690",TEST,HY
171,2793,5079604,The restricted mean time to hyperglycemia relapse,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,significantly increased,1,continuous,,33,,15,480,,305,,cannot calculate,cannot calculate,,,,,SD is not given.,FALSE,FALSE,FALSE,FALSE,"12,690",TEST,HY
172,2790,5079604,Hyperglycemia relapse-free survival,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,significantly increased,1,continuous,,33,,15,,,,,cannot calculate,cannot calculate,,,,,Data is in figure.,TRUE,FALSE,FALSE,FALSE,"12,690",TEST,HY
173,2791,5079604,The 2-year failure rate,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,significantly decreased,-1,binary,13,33,12,15,,,,,,,-1.8171,0.5436,-0.7084,0.0633,Used percentage to calculate events as binary outcome.,TRUE,TRUE,FALSE,TRUE,"12,690",TEST,HY
174,2796,5079604,The probability of relapse,"metformin 1,000 mg daily, sitagliptin 100 mg daily",placebo,significantly decreased,-1,binary,9,33,11,15,,,,,,,-1.9924,0.4937,-0.9891,0.1051,Used percentage to calculate events as binary outcome.,FALSE,FALSE,FALSE,TRUE,"12,690",TEST,HY
175,10752,5086025,Intuitive eating total score,Intuitive Eating and Acceptance and Commitment Therapy,Control,significantly increased,1,continuous,,26,,26,3.45,0.55,2.54,0.58,1.5858,0.1011,,,,,Actually comparing preintervention and postintervention,FALSE,TRUE,FALSE,TRUE,"29,049",TEST,HY
176,10753,5086025,Psychological flexibility,Intuitive Eating and Acceptance and Commitment Therapy,Control,significantly increased,1,continuous,,26,,26,18.23,8.14,22.46,8.67,-0.4954,0.0793,,,,,Actually psychological inflexibility in the article,FALSE,TRUE,FALSE,TRUE,"29,049",TEST,HY
177,10754,5086025,General mental health,Intuitive Eating and Acceptance and Commitment Therapy,Control,significantly increased,1,continuous,,26,,26,50.24,7.41,45.63,6.31,0.6598,0.0811,,,,,,FALSE,TRUE,FALSE,TRUE,"29,049",TEST,HY
178,10755,5086025,Binge eating,Intuitive Eating and Acceptance and Commitment Therapy,Control,significantly decreased,-1,binary,7,26,14,26,,,,,,,-1.1527,0.3503,-0.6931,0.1374,,FALSE,FALSE,FALSE,TRUE,"29,049",TEST,HY
179,10756,5086025,BMI,Intuitive Eating and Acceptance and Commitment Therapy,Control,no significant difference,0,continuous,,26,,26,32.81,5.31,32.93,4.85,-0.0232,0.0769,,,,,,FALSE,TRUE,FALSE,TRUE,"29,049",TEST,HY
180,10757,5086025,General physical health,Intuitive Eating and Acceptance and Commitment Therapy,Control,no significant difference,0,continuous,,26,,26,50.87,11.02,50.46,7.83,0.0422,0.0769,,,,,,FALSE,TRUE,FALSE,TRUE,"29,049",TEST,HY
181,4339,5122613,Left SCTT,Digestion-resistant maltodextrin,Placebo,significantly decreased,-1,continuous,,29,,28,10.2,8.6,12.1,9.5,-0.207,0.0706,,,,,Had to do some simple math to get accurate group size.,FALSE,TRUE,FALSE,TRUE,"6,184",TEST,HY
182,4340,5122613,Adverse events,Digestion-resistant maltodextrin,Placebo,no significant difference,0,binary,0,33,0,33,,,,,,,0,4.0597,0,3.9412,Based on abstract.,FALSE,FALSE,FALSE,TRUE,"6,184",TEST,HY
183,4341,5122613,Baseline characteristics and diet,Digestion-resistant maltodextrin,Placebo,no significant difference,0,continuous,,33,,33,10,4.6,11.5,4.6,-0.3222,0.0614,,,,,Mean daily fiber intake,FALSE,FALSE,FALSE,TRUE,"6,184",TEST,HY
184,4337,5122613,Improvement in faeces consistency,Digestion-resistant maltodextrin,Placebo,significantly increased,1,continuous,,33,,33,3.4,1,3.2,0.5,0.25,0.0611,,,,,,FALSE,TRUE,FALSE,TRUE,"6,184",TEST,HY
185,4338,5122613,Colonic transit time,Digestion-resistant maltodextrin,Placebo,significantly decreased,-1,continuous,,29,,28,39.7,22.3,48,25,-0.3459,0.0712,,,,,,FALSE,TRUE,FALSE,TRUE,"6,184",TEST,HY
186,13818,5244530,depression severity reduction,person-centred general practitioners (GP) consultations,treatment as usual (TAU),no significant difference,0,continuous,,125,,133,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,FALSE,FALSE,"6,216",DEV,HY
187,13818,5244530,remission rate,person-centred general practitioners (GP) consultations,treatment as usual (TAU),no significant difference,0,continuous,,125,,133,,,,,cannot calculate,cannot calculate,,,,,,FALSE,FALSE,FALSE,FALSE,"6,216",DEV,HY
188,13818,5244530,change in quality of life,person-centred general practitioners (GP) consultations,treatment as usual (TAU),no significant difference,0,continuous,,125,,133,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,FALSE,FALSE,"6,216",DEV,HY
189,13818,5244530,psychological well-being,person-centred general practitioners (GP) consultations,treatment as usual (TAU),no significant difference,0,continuous,,125,,133,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,FALSE,FALSE,"6,216",DEV,HY
190,13818,5244530,sedative prescriptions,person-centred general practitioners (GP) consultations,treatment as usual (TAU),no significant difference,0,binary,52,125,51,133,,,,,,,0.1357,0.0647,0.0815,0.0233,Data from 12 months follow up (final timepoint),FALSE,TRUE,FALSE,TRUE,"6,216",DEV,HY
191,13818,5244530,sick leave,person-centred general practitioners (GP) consultations,treatment as usual (TAU),no significant difference,0,binary,49,125,64,133,,,,,,,-0.3637,0.0637,-0.205,0.0205,,FALSE,TRUE,FALSE,TRUE,"6,216",DEV,HY
192,13819,5244530,continued antidepressants until the 6-month,person-centred general practitioners (GP) consultations,treatment as usual (TAU),significantly increased,1,binary,86,125,78,133,,,,,,,0.4414,0.0683,0.1597,0.0089,,FALSE,TRUE,FALSE,TRUE,"6,216",DEV,HY
193,2094,5360580,Plasma PlsPE,1 mg/day of Pls purified from scallop,placebo,significantly increased,1,continuous,,138,,131,-0.59,1.11,-0.63,1.08,0.0364,0.0149,,,,,Data is from after 28 weeks (final timepoint). Back calculated the SD values using CI values.,FALSE,TRUE,FALSE,TRUE,"11,096",TEST,HY
194,2095,5360580,occurrence of adverse events,1 mg/day of Pls purified from scallop,placebo,no significant difference,0,binary,39,169,35,167,,,,,,,0.1235,0.0695,0.0963,0.0423,,FALSE,TRUE,FALSE,TRUE,"11,096",TEST,HY
195,2096,5360580,"WMS-R (30 min) In the patients aged 77 years or younger,",1 mg/day of Pls purified from scallop,placebo,significantly increased,1,continuous,,19,,21,1.84,3.87,0,0.96,0.6551,0.1056,,,,,Data is from 24 weeks (final timepoint). Back calculated the SD values using CI values.,FALSE,TRUE,FALSE,TRUE,"11,096",TEST,HY
196,2097,5360580,WMS-R (0 min),1 mg/day of Pls purified from scallop,placebo,no significant difference,0,continuous,,24,,24,1.29,3.14,1.08,1.55,0.0834,0.0834,,,,,Data is from 28 weeks (final timepoint). Back calculated the SD values using CI values.,FALSE,TRUE,FALSE,TRUE,"11,096",TEST,HY
197,7734,5380284,Pain scores 48 hours after the surgery,Gum-chewing group,No gum group,significantly increased,1,continuous,,38,,37,,,,,cannot calculate,cannot calculate,,,,,,FALSE,TRUE,TRUE,FALSE,"1,731",TEST,HY
198,7735,5380284,Surgery duration,Gum-chewing group,No gum group,no significant difference,0,continuous,,38,,37,,,,,cannot calculate,cannot calculate,,,,,Data is unavailable.,FALSE,FALSE,TRUE,FALSE,"1,731",TEST,HY
199,7736,5380284,Rates of POI,Gum-chewing group,No gum group,no significant difference,0,continuous,,38,,37,,,,,cannot calculate,cannot calculate,,,,,,FALSE,TRUE,TRUE,FALSE,"1,731",TEST,HY
200,7737,5380284,Consumption of fentanyl,Gum-chewing group,No gum group,no significant difference,0,continuous,,38,,37,,,,,cannot calculate,cannot calculate,,,,,,FALSE,TRUE,TRUE,FALSE,"1,731",TEST,HY
201,7738,5380284,Pain scores 24 hours and 72 hours after the surgery,Gum-chewing group,No gum group,no significant difference,0,continuous,,38,,37,,,,,cannot calculate,cannot calculate,,,,,,FALSE,TRUE,TRUE,FALSE,"1,731",TEST,HY
202,5498,5380326,Interferon gamma-induced protein 10,Vitamin D supplementation,Control,significantly decreased,-1,continuous,,40,,40,636.47,448.47,748.88,551,-0.2216,0.0503,,,,,,FALSE,TRUE,FALSE,TRUE,"10,658",TEST,HY
203,5496,5380326,Vitamin D levels,Vitamin D supplementation,Control,significantly increased,1,continuous,,40,,40,45.93,15.37,21.87,5.31,2.0722,0.0768,,,,,,FALSE,TRUE,FALSE,TRUE,"10,658",TEST,HY
204,5497,5380326,Th1/Th2 cytokines,Vitamin D supplementation,Control,no significant difference,0,continuous,,40,,40,,,,,cannot calculate,cannot calculate,,,,,Unclear outcome numerical values in the RCT. Cannot clearly identify the actual metric or measure for the given outcome.,FALSE,FALSE,FALSE,FALSE,"10,658",TEST,HY
205,5500,5380326,Interleukin 2,Vitamin D supplementation,Control,no significant difference,0,continuous,,40,,40,4.49,13.34,28.69,103.03,-0.2276,0.0503,,,,,,FALSE,TRUE,FALSE,TRUE,"10,658",TEST,HY
206,5499,5380326,Dipeptidyl peptidase-4,Vitamin D supplementation,Control,significantly decreased,-1,continuous,,40,,40,"6,032.37",1359.15,6408.33,1822.17,-0.2316,0.0503,,,,,Table and text has conflicting numbers. Values are from Table.,FALSE,FALSE,FALSE,TRUE,"10,658",TEST,HY
207,5501,5380326,Tumor necrosis factor alpha,Vitamin D supplementation,Control,no significant difference,0,continuous,,40,,40,752.94,1890.16,548.33,1210.9,0.1277,0.0501,,,,,,FALSE,TRUE,FALSE,TRUE,"10,658",TEST,HY
208,2913,5459456,inflexion-extension for the C2-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,no significant difference,0,continuous,,8,,8,6.3,1.1,6.5,0.9,-0.1881,0.2511,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
209,2913,5459456,inflexion-extension for the C2-C4 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,no significant difference,0,continuous,,8,,8,4,0.3,4,0.6,1.9928,0.3741,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
210,2913,5459456,inflexion-extension for the C4-C5 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,no significant difference,0,continuous,,8,,8,1.4,0.3,1.3,0.2,0.3708,0.2543,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
211,2913,5459456,inflexion-extension for the C5-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,no significant difference,0,continuous,,8,,8,1.4,0.1,1.4,0.2,0,0.25,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
212,2913,5459456,lateral bending for the C2-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,no significant difference,0,continuous,,8,,8,9.2,0.9,9.6,1.1,-0.3762,0.2544,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
213,2913,5459456,lateral bending for the C2-C4 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,no significant difference,0,continuous,,8,,8,5.8,0.5,5.9,0.7,-0.1554,0.2508,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
214,2913,5459456,lateral bending for the C4-C5 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,no significant difference,0,continuous,,8,,8,2,0.4,1.8,0.2,0.5979,0.2612,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
215,2913,5459456,lateral bending for the C5-C6 segments,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,control,no significant difference,0,continuous,,8,,8,2.2,0.4,2,0.3,0.5347,0.2589,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
216,2915,5459456,new bone formation around the screws and bone-implant contact (BIC) in both sections,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating,ACVC,significantly increased,1,continuous,,8,,8,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,FALSE,FALSE,"13,404",TEST,HY
217,2912,5459456,surgery time,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),no significant difference,0,continuous,,8,,8,67,16,65,13,0.1297,0.2505,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
218,2912,5459456,blood loss,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),no significant difference,0,continuous,,8,,8,56,19,51,20,0.2423,0.2518,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
219,2912,5459456,recovery time,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),no significant difference,0,continuous,,8,,8,4.1,2,3.5,1.4,0.3286,0.2534,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
220,2912,5459456,time before eating,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),no significant difference,0,continuous,,8,,8,4.5,2.2,3.9,2.3,0.6791,0.2644,,,,,,FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
221,2914,5459456,Flexion-Extension stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),significantly decreased,-1,continuous,,8,,8,0.34,0.12,7.47,1.45,-6.5512,1.5912,,,,,"Data is from after fatigue test. Original outcome was just ""The stiffness"".",FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
222,2914,5459456,Lateral bending stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),significantly decreased,-1,continuous,,8,,8,0.05,0.02,2.67,0.68,-5.1485,1.0784,,,,,"Data is from after fatigue test. Original outcome was just ""The stiffness"".",FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
223,2914,5459456,Rotation stiffness of C2-4,ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC,anterior cervical corpectomy and fusion (ACCF),significantly decreased,-1,continuous,,8,,8,0.02,0,1.62,0.47,-4.5509,0.8972,,,,,"Data is from after fatigue test. Original outcome was just ""The stiffness"".",FALSE,TRUE,FALSE,TRUE,"13,404",TEST,HY
224,3486,5498715,Scores of external regulation,Motivational interviewing through self-determination theory sessions,Standard education session,significantly decreased,-1,continuous,,35,,35,0.3,0.79,0.38,0.98,-0.0889,0.0572,,,,,,FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
225,3486,5498715,Scores of amotivation,Motivational interviewing through self-determination theory sessions,Standard education session,significantly decreased,-1,continuous,,35,,35,0.33,1.06,0.7,1.24,-0.3172,0.0579,,,,,,FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
226,3487,5498715,Body mass index,Motivational interviewing through self-determination theory sessions,Standard education session,significantly decreased,-1,continuous,,35,,35,25.78,3.3,26.53,3.53,-0.2171,0.0575,,,,,,FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
227,3484,5498715,Sedentary behavior,Motivational interviewing through self-determination theory sessions,Standard education session,significantly decreased,-1,continuous,,35,,35,5.28,2.34,5.75,2.34,-0.1986,0.0574,,,,,,FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
228,3484,5498715,agility test,Motivational interviewing through self-determination theory sessions,Standard education session,significantly decreased,-1,continuous,,35,,35,13.21,1.44,13.8,1.14,-0.4493,0.0586,,,,,Data from followup.,FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
229,3483,5498715,Physical activity,Motivational interviewing through self-determination theory sessions,Standard education session,significantly increased,1,continuous,,35,,35,487.33,111.47,453.57,60.87,0.3718,0.0581,,,,,,FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
230,3483,5498715,physical fitness - flexibility,Motivational interviewing through self-determination theory sessions,Standard education session,significantly increased,1,continuous,,35,,35,35.53,5.87,26.83,5.47,1.5165,0.0736,,,,,"Original outcome was ""physical fitness""",FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
231,3483,5498715,physical fitness - muscular endurance,Motivational interviewing through self-determination theory sessions,Standard education session,significantly increased,1,continuous,,35,,35,17.83,2.7,12.48,2.9,1.8883,0.0826,,,,,"Original outcome was ""physical fitness""",FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
232,3483,5498715,physical fitness - agility,Motivational interviewing through self-determination theory sessions,Standard education session,significantly increased,1,continuous,,35,,35,13.21,1.44,13.8,1.14,-0.4493,0.0586,,,,,"Original outcome was ""physical fitness""",FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
233,3483,5498715,physical fitness - cardiorespiratory endurance,Motivational interviewing through self-determination theory sessions,Standard education session,significantly increased,1,continuous,,35,,35,39.1,2.76,37.99,2.14,0.4445,0.0586,,,,,"Original outcome was ""physical fitness""",FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
234,3485,5498715,Scores of intrinsic motivation,Motivational interviewing through self-determination theory sessions,Standard education session,significantly increased,1,continuous,,35,,35,10.8,2,4.9,1.88,3.0061,0.1217,,,,,,FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
235,3485,5498715,Scores of perception of competence,Motivational interviewing through self-determination theory sessions,Standard education session,significantly increased,1,continuous,,35,,35,13.6,3.05,14.71,3.87,-0.3151,0.0579,,,,,,FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
236,3485,5498715,Scores of perception of autonomy,Motivational interviewing through self-determination theory sessions,Standard education session,significantly increased,1,continuous,,35,,35,26.6,4.43,19.89,4.56,1.4761,0.0727,,,,,,FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
237,3485,5498715,Scores of enjoyment,Motivational interviewing through self-determination theory sessions,Standard education session,significantly increased,1,continuous,,35,,35,27.3,6.77,26,4.68,0.2209,0.0575,,,,,,FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
238,3485,5498715,Scores of health care climate,Motivational interviewing through self-determination theory sessions,Standard education session,significantly increased,1,continuous,,35,,35,80.5,9.97,69.89,1.59,1.4698,0.0726,,,,,,FALSE,TRUE,FALSE,TRUE,"11,299",DEV,HY
239,8054,5534041,composite z-scores in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,significantly increased,1,continuous,,12,,12,0.11,0.81,-0.25,0.71,0.4563,0.171,,,,,,FALSE,TRUE,FALSE,TRUE,"6,951",TEST,HY
240,8055,5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,significantly increased,1,continuous,,12,,12,6,0.9,4.8,0.9,1.2873,0.2012,,,,,,FALSE,TRUE,FALSE,TRUE,"6,951",TEST,HY
241,8053,5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),right dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),no significant difference,0,continuous,,12,,12,6,0.9,6.2,1.8,-0.1357,0.1671,,,,,,FALSE,TRUE,FALSE,TRUE,"6,951",TEST,HY
242,8056,5534041,overall working memory (WM) performance in autism spectrum disorder (ASD),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,significantly increased,1,continuous,,12,,12,6.2,1.8,4.8,0.9,0.9498,0.1855,,,,,,FALSE,TRUE,FALSE,TRUE,"6,951",TEST,HY
243,8057,5534041,composite z-scores in autism spectrum disorder (ASD),left dorsolateral prefrontal cortex (DLPFC) anodal transcranial direct current stimulation (tDCS),sham stimulation,significantly increased,1,continuous,,12,,12,0.13,0.82,-0.25,0.71,0.4783,0.1714,,,,,,FALSE,TRUE,FALSE,TRUE,"6,951",TEST,HY
244,10306,5571493,Glycemic level,Dw 5% with Quinine infusion,Dw 5% without Quinine infusion,significantly decreased,-1,continuous,,10,,10,0.82,0.05,0.92,0.07,-1.5744,0.262,,,,,,FALSE,FALSE,FALSE,TRUE,"1,507",TEST,HY
245,10307,5571493,Glycemic level,Saline + Quinine infusion,Dw 5% + Quinine infusion,no significant difference,0,continuous,,10,,10,0.74,0.05,0.82,0.05,-1.5322,0.2587,,,,,,FALSE,FALSE,FALSE,TRUE,"1,507",TEST,HY
246,10305,5571493,Glycemic level,Saline + Quinine infusion,Saline without Quinine infusion,significantly decreased,-1,continuous,,10,,10,0.74,0.05,0.83,0.05,-1.7238,0.2743,,,,,,FALSE,FALSE,FALSE,TRUE,"1,507",TEST,HY
247,10308,5571493,QT interval,Saline + Quinine infusion,Saline without Quinine infusion,no significant difference,0,continuous,,10,,10,,,,,cannot calculate,cannot calculate,,,,,No numerical values are given.,FALSE,FALSE,FALSE,FALSE,"1,507",TEST,HY
248,10309,5571493,QT interval,Dw 5%+ Quinine infusion,Dw 5% without Quinine infusion,no significant difference,0,continuous,,10,,10,,,,,cannot calculate,cannot calculate,,,,,No numerical values are given.,FALSE,FALSE,FALSE,FALSE,"1,507",TEST,HY
249,10310,5571493,Hypoglycemia,Saline + Quinine infusion,Saline without Quinine infusion,no significant difference,0,continuous,,10,,10,,,,,cannot calculate,cannot calculate,,,,,No numerical values are given.,FALSE,FALSE,FALSE,FALSE,"1,507",TEST,HY
250,12425,5614421,The incidence of respiratory distress syndrome,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,no significant difference,0,binary,42,402,41,388,,,,,,,-0.0127,0.0539,-0.0113,0.0431,,FALSE,TRUE,FALSE,TRUE,"25,930",TEST,HY
251,12426,5614421,severity of any neonatal respiratory disease,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,no significant difference,0,binary,8,402,7,388,,,,,,,0.1,0.273,0.0981,0.2628,,FALSE,TRUE,FALSE,TRUE,"25,930",TEST,HY
252,12427,5614421,other respiratory morbidities,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,no significant difference,0,binary,,402,,388,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,,FALSE,FALSE,FALSE,FALSE,"25,930",TEST,HY
253,12427,5614421,"adverse infant outcomes, including serious infant composite outcome",vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,no significant difference,0,binary,155,406,152,393,,,,,,,-0.0211,0.0212,-0.013,0.008,,FALSE,TRUE,FALSE,TRUE,"25,930",TEST,HY
254,12428,5614421,side effects,vaginal progesterone pessaries (equivalent to 100 mg vaginal progesterone),placebo,no significant difference,0,binary,134,394,118,382,,,,,,,0.1424,0.0236,0.0962,0.0108,,FALSE,TRUE,FALSE,TRUE,"25,930",TEST,HY
255,10572,5711682,In-stent late lumen loss at 9 months,Genoss drug-eluting stent (DES),Promus Element,no significant difference,0,continuous,,38,,39,0.11,0.25,0.16,0.43,-0.1361,0.2005,,,,,,FALSE,TRUE,FALSE,TRUE,"13,148",TEST,HY
256,10573,5711682,myocardial infarction (MI),Genoss drug-eluting stent (DES),Promus Element,no significant difference,0,binary,0,38,0,39,,,,,,,0.0256,4.0513,0.0253,3.9494,,FALSE,TRUE,FALSE,TRUE,"13,148",TEST,HY
257,10571,5711682,target lesion revascularization (TLR),Genoss drug-eluting stent (DES),Promus Element,no significant difference,0,binary,1,38,1,39,,,,,,,0.0267,2.0533,0.026,1.948,,FALSE,TRUE,FALSE,TRUE,"13,148",TEST,HY
258,10574,5711682,stent thrombosis,Genoss drug-eluting stent (DES),Promus Element,no significant difference,0,binary,0,38,0,39,,,,,,,0.0256,4.0513,0.0253,3.9494,,FALSE,TRUE,FALSE,TRUE,"13,148",TEST,HY
259,10575,5711682,rates of death,Genoss drug-eluting stent (DES),Promus Element,no significant difference,0,binary,1,38,0,39,,,,,,,1.1506,2.7186,1.1239,2.616,,FALSE,TRUE,FALSE,TRUE,"13,148",TEST,HY
260,13181,5771543,CGI-I response rate,fluoxetine,placebo,significantly increased,1,binary,79,101,62,99,,,,,,,0.7622,0.1013,0.2223,0.0088,,FALSE,TRUE,FALSE,TRUE,"12,534",DEV,HY
261,13182,5771543,CGI-I response rate,desvenlafaxine,placebo,no significant difference,0,binary,68,99,62,99,,,,,,,0.2693,0.0901,0.0924,0.0106,,FALSE,TRUE,FALSE,TRUE,"12,534",DEV,HY
262,13183,5771543,Treatment-emergent adverse events (TEAEs),desvenlafaxine,placebo,no significant difference,0,binary,69,115,79,112,,,,,,,-0.4675,0.0792,-0.1618,0.0095,,FALSE,TRUE,FALSE,TRUE,"12,534",DEV,HY
263,13183,5771543,Treatment-emergent adverse events (TEAEs),fluoxetine,placebo,no significant difference,0,binary,72,112,79,112,,,,,,,-0.2852,0.0819,-0.0928,0.0087,Typo in the table,FALSE,TRUE,FALSE,TRUE,"12,534",DEV,HY
264,2786,2430617,HBeAg sero-conversion rate,60 µg of immune complexes (YIC),placebo,significantly increased,1,binary,17,80,7,79,,,,,,,1.0208,0.2314,0.8747,0.1765,effects found in abstract and exact number in results table,FALSE,TRUE,FALSE,TRUE,7987,TEST,DP
265,2787,2430617,adverse events,30 µg YIC,placebo,no significant difference,0,binary,,,,,,,,,,,,,,,,FALSE,TRUE,FALSE,TRUE,7987,TEST,DP
266,2787,2430617,adverse events,60 µg of YIC,placebo,no significant difference,0,binary,7,163,4,79,,,,,,,-0.1728,0.4126,-0.1647,0.3741,effects found in abstract and number of samples in text,FALSE,FALSE,FALSE,TRUE,7987,TEST,DP
267,12440,2596788,GERD-knowledge,education,control,significantly increased,1,continuous,,102,,109,,,,,cannot calculate,cannot calculate,,,,,no standard deviations given or mean differences,TRUE,FALSE,FALSE,FALSE,5143,TEST,DP
268,2991,3214395,laryngoscopy duration,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 45",group 3 involved bispectral index (BIS) of 35,no significant difference,0,continuous,,60,,30,,,,,cannot calculate,cannot calculate,,,,,mean and std not given for group 1 and 2 combined,FALSE,TRUE,TRUE,FALSE,1201,TEST,DP
269,2991,3214395,laryngospasm,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 46",group 3 involved bispectral index (BIS) of 36,no significant difference,0,binary,11,60,3,30,,,,,,,0.7033,0.4817,0.6061,0.3742,,FALSE,TRUE,TRUE,TRUE,1201,TEST,DP
270,2991,3214395,bronchospasm,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 47",group 3 involved bispectral index (BIS) of 37,no significant difference,0,binary,1,60,0,30,,,,,,,0.4304,2.7163,0.4217,2.618,,FALSE,TRUE,TRUE,TRUE,1201,TEST,DP
271,2991,3214395,laryngoscopy failure,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 48",group 3 involved bispectral index (BIS) of 38,no significant difference,0,continuous,,60,,30,,,,,cannot calculate,cannot calculate,,,,,mean and std not given for group 1 and 2 combined,FALSE,TRUE,TRUE,FALSE,1201,TEST,DP
272,2991,3214395,extremity movement,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 49",group 3 involved bispectral index (BIS) of 39,no significant difference,0,binary,16,60,9,30,,,,,,,-0.1643,0.244,-0.1178,0.1236,,FALSE,TRUE,TRUE,TRUE,1201,TEST,DP
273,2991,3214395,awakening,"group 1 included bispectral index (BIS) of 60, group 2 covered bispectral index (BIS) of 50",group 3 involved bispectral index (BIS) of 40,no significant difference,0,continuous,,60,,30,,,,,cannot calculate,cannot calculate,,,,,mean and std not given for group 1 and 2 combined,FALSE,TRUE,TRUE,FALSE,1201,TEST,DP
274,6419,3654355,Body weight,Intensive lifestyle intervention (ILI) group,Waiting list control,significantly decreased,-1,continuous,,71,,33,-17.5,6.1,-0.5,2.8,-3.1892,0.0933,,,,,,FALSE,TRUE,FALSE,TRUE,18948,TEST,DP
275,6420,3654355,Fat mass,Intensive lifestyle intervention (ILI) group,Waiting list control,significantly decreased,-1,continuous,,71,,33,-15.7,5.3,-0.4,5,-2.9163,0.0853,,,,,,FALSE,TRUE,FALSE,TRUE,18948,TEST,DP
276,6421,3654355,Visceral fat,Intensive lifestyle intervention (ILI) group,Waiting list control,significantly decreased,-1,continuous,,71,,33,-82.3,31.6,4.3,22.7,-2.6604,0.0784,,,,,,FALSE,TRUE,FALSE,TRUE,18948,TEST,DP
277,6422,3654355,Baseline Height,Intensive lifestyle intervention (ILI) group,Waiting list control,no significant difference,0,continuous,,71,,33,173.2,8.6,172.3,10.4,0.0971,0.0444,,,,,,FALSE,TRUE,FALSE,TRUE,18948,TEST,DP
278,6422,3654355,Baseline body mass index,Intensive lifestyle intervention (ILI) group,Waiting list control,no significant difference,0,continuous,,71,,33,42.8,4.6,42.8,6.3,0,0.0444,,,,,,FALSE,TRUE,FALSE,TRUE,18948,TEST,DP
279,6422,3654355,baseline body weight,Intensive lifestyle intervention (ILI) group,Waiting list control,no significant difference,0,continuous,,71,,33,128.9,19.4,127.1,21.6,0.0888,0.0444,,,,,,FALSE,TRUE,FALSE,TRUE,18948,TEST,DP
280,6422,3654355,baseline fat mass,Intensive lifestyle intervention (ILI) group,Waiting list control,no significant difference,0,continuous,,71,,33,60.5,11,60.4,13.5,0.0084,0.0444,,,,,,FALSE,TRUE,FALSE,TRUE,18948,TEST,DP
281,6422,3654355,baseline fat-free mass,Intensive lifestyle intervention (ILI) group,Waiting list control,no significant difference,0,continuous,,71,,33,68.3,13.2,67.1,12.8,0.0911,0.0444,,,,,,FALSE,TRUE,FALSE,TRUE,18948,TEST,DP
282,6422,3654355,baseline skeletal muscle mass,Intensive lifestyle intervention (ILI) group,Waiting list control,no significant difference,0,continuous,,71,,33,38.4,7.9,37.9,7.4,0.0641,0.0444,,,,,,FALSE,TRUE,FALSE,TRUE,18948,TEST,DP
283,6422,3654355,baseline visceral fat area,Intensive lifestyle intervention (ILI) group,Waiting list control,no significant difference,0,continuous,,71,,33,255.7,64.7,245.6,66.3,0.1538,0.0445,,,,,,FALSE,TRUE,FALSE,TRUE,18948,TEST,DP
284,6301,3929816,Baseline characteristics and general anesthesia procedure,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,no significant difference,0,continuous,,10,,10,,,,,cannot calculate,cannot calculate,,,,,No quantitative measures given,FALSE,FALSE,FALSE,FALSE,1047,TEST,DP
285,6302,3929816,Pathologic changes in the liver,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,no significant difference,0,continuous,,10,,10,,,,,cannot calculate,cannot calculate,,,,,No quantitative measures given,FALSE,FALSE,FALSE,FALSE,1047,TEST,DP
286,6303,3929816,Pathologic changes in the kidneys,Intraabdominal pressure 20 mm Hg,Intraabdominal pressure 12 mm Hg,significantly increased,1,continuous,,10,,10,20,,,,cannot calculate,cannot calculate,,,,,Not enough measures given for calculation,FALSE,FALSE,FALSE,FALSE,1047,TEST,DP
287,6100,4215531,alpha power,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,significantly increased,1,continuous,,19,,19,,,,,cannot calculate,cannot calculate,,,,,"F-values given, not sure how to use them",FALSE,FALSE,FALSE,FALSE,7350,TEST,DP
288,6102,4215531,alpha power,facial affect training (FAT) in 20 daily 1-hour sessions,treatment as usual (TAU),significantly increased,1,continuous,,19,,19,,,,,cannot calculate,cannot calculate,,,,,"F-values given, not sure how to use them",FALSE,FALSE,FALSE,FALSE,7350,TEST,DP
289,6103,4215531,MCCB performance : Processing Speed,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,significantly increased,1,continuous,,19,,19,44.6,12.2,48.2,12.3,-0.2877,0.1064,,,,,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7350,TEST,DP
290,6103,4215531,MCCB performance : Attentional Vigilance,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,significantly increased,1,continuous,,19,,19,38.5,11.8,41.3,10.1,-0.2496,0.1061,,,,,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7350,TEST,DP
291,6103,4215531,MCCB performance : Visual Learning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,significantly increased,1,continuous,,19,,19,49.4,12.8,46.5,9.8,0.2491,0.1061,,,,,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7350,TEST,DP
292,6104,4215531,MCCB performance : Working Memory,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,no significant difference,0,continuous,,19,,19,48.2,9.2,50.8,12.1,-0.2368,0.106,,,,,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7351,TEST,DP
293,6104,4215531,MCCB performance : Verbal Learning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,no significant difference,0,continuous,,19,,19,47.1,10,47.3,10.4,-0.0192,0.1053,,,,,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7352,TEST,DP
294,6104,4215531,MCCB performance : Reasoning,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,no significant difference,0,continuous,,19,,19,47.9,8.8,46.5,9.8,0.1472,0.1055,,,,,used post values and Treatment as Usual as Baseline,FALSE,TRUE,FALSE,TRUE,7353,TEST,DP
295,6104,4215531,MCCB performance : Social Cognition,facial affect training (FAT) in 20 daily 1-hour sessions,baseline,no significant difference,0,continuous,,19,,19,39.3,11.1,42.8,11.7,-0.3005,0.1065,,,,,used post values and Treatment as Usual as Baseline,FALSE,FALSE,FALSE,FALSE,7350,TEST,DP
296,5595,4355974,Days of wheeze,BostonBreathes system,Control,no significant difference,0,continuous,,28,,14,-1.4,,-4.2,,,,,,,,standard deviations not given and means are mean change,FALSE,TRUE,FALSE,FALSE,7450,TEST,DP
297,5596,4355974,ER visits,BostonBreathes system,Control,no significant difference,0,binary,1,28,1,14,,,,,,,-0.7309,2.114,-0.6931,1.8929,found in table,FALSE,TRUE,FALSE,TRUE,7450,TEST,DP
298,5597,4355974,Days limited activity from asthma,BostonBreathes system,Control,no significant difference,0,continuous,,28,,14,-0.2,,-1.8,,cannot calculate,cannot calculate,,,,,"standard deviations not given, means are mean change",FALSE,TRUE,FALSE,FALSE,7450,TEST,DP
299,5598,4355974,Knowledge,BostonBreathes system,Control,significantly increased,1,binary,9,12,3,8,,,,,,,1.6094,0.9778,0.6931,0.2361,"found in table,",FALSE,TRUE,FALSE,TRUE,7450,TEST,DP
300,5599,4355974,School days missed for asthma,BostonBreathes system,Control,no significant difference,0,continuous,,28,,14,-0.2,,-0.4,,cannot calculate,cannot calculate,,,,,"standard deviations not given, means are mean change",FALSE,TRUE,FALSE,FALSE,7450,TEST,DP
301,5600,4355974,Days patient had to slow down,BostonBreathes system,Control,no significant difference,0,continuous,,28,,14,-1.4,,-0.4,,cannot calculate,cannot calculate,,,,,"standard deviations not given, means are mean change",FALSE,TRUE,FALSE,FALSE,7450,TEST,DP
302,3878,4357072,improvement in symptom scores,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,significantly increased,1,continuous,,15,,15,0.2,0.4,0.8,0.6,-1.1448,0.1552,,,,,significance found in abstract and numbers in results,FALSE,TRUE,TRUE,TRUE,2097,TEST,DP
303,3879,4357072,reduction in burning sensation,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,no significant difference,0,continuous,,15,,15,1,2.1,5.3,6.1,-0.9171,0.1474,,,,,significance found in abstract and numbers in results,FALSE,TRUE,TRUE,TRUE,2097,TEST,DP
304,3880,4357072,reduction in erythematous area,topical pimecrolimus cream 1%,triamcinolone acetonide oral paste 0.1%,no significant difference,0,binary,14,15,10,15,,,,,,,1.9459,1.3714,0.3365,0.0381,significance found in abstract and numbers in results,FALSE,TRUE,TRUE,TRUE,2097,TEST,DP
305,3882,4357072,reappearance of erythematous areas after 2 months posttreatment,pimecrolimus,triamcinolone acetate,no significant difference,0,binary,1,15,5,15,,,,,,,-1.9459,1.3714,-1.6094,1.0667,significance found in abstract and numbers in results,FALSE,TRUE,FALSE,TRUE,2097,TEST,DP
306,7831,4541185,duration of sensory block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,significantly increased,1,continuous,,30,,30,703.83,42.9,556.38,37.96,3.5929,0.1742,,,,,found in text,FALSE,TRUE,TRUE,TRUE,1359,TEST,DP
307,7831,4541185,duration of motor block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,significantly increased,1,continuous,,30,,30,621.67,46.76,500.86,44.58,2.6102,0.1234,,,,,found in text,FALSE,TRUE,TRUE,TRUE,1359,TEST,DP
308,7832,4541185,duration of analgesia,ropivacaine + diluted clonidine with saline,ropivacaine + saline,significantly increased,1,continuous,,30,,30,878.33,89.955,613.1,51.797,2.7597,0.1301,,,,,found in text,FALSE,TRUE,TRUE,TRUE,1359,TEST,DP
309,7833,4541185,onset of sensory block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,significantly decreased,-1,continuous,,30,,30,4.36,0.81,4.84,0.65,-0.6451,0.0701,,,,,found in abstract,FALSE,FALSE,FALSE,TRUE,1359,TEST,DP
310,7833,4541185,onset of motor block,ropivacaine + diluted clonidine with saline,ropivacaine + saline,significantly decreased,-1,continuous,,30,,30,9.83,1.12,10.85,0.79,-1.0388,0.0757,,,,,found in abstract,FALSE,FALSE,FALSE,TRUE,1359,TEST,DP
311,7834,4541185,drop in heart rate,ropivacaine + diluted clonidine with saline,ropivacaine + saline,significantly increased,1,continuous,,30,,30,76.1,8.91,76.77,8.76,-0.0748,0.0667,,,,,found in table,FALSE,TRUE,TRUE,TRUE,1359,TEST,DP
312,7835,4541185,drop in mean arterial pressure,ropivacaine + diluted clonidine with saline,ropivacaine + saline,no significant difference,0,continuous,,30,,30,91.2,6.62,92.04,7.15,-0.1203,0.0668,,,,,found in table,FALSE,TRUE,TRUE,TRUE,1359,TEST,DP
313,9840,4928400,Stone-free rate,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,significantly increased,1,binary,22,22,16,20,,,,,,,2.5074,2.3273,0.2192,0.014,,FALSE,TRUE,FALSE,TRUE,4037,TEST,DP
314,9841,4928400,Operative time,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,no significant difference,0,continuous,,22,,20,74.1,12.2,78,6.4,-0.3985,0.0973,,,,,found in table,FALSE,TRUE,FALSE,TRUE,4037,TEST,DP
315,9842,4928400,Complication,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,no significant difference,0,binary,5,22,7,20,,,,,,,-0.6047,0.4786,-0.4318,0.2474,,FALSE,TRUE,FALSE,TRUE,4037,TEST,DP
316,9843,4928400,Postoperative pain,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,significantly increased,1,continuous,,22,,20,4.3,1,3.6,1.2,0.619,0.1,,,,,,FALSE,TRUE,FALSE,TRUE,4037,TEST,DP
317,9844,4928400,Hospital stay,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,significantly increased,1,continuous,,22,,20,4.2,1.2,2.1,1.1,1.7938,0.1338,,,,,,FALSE,TRUE,FALSE,TRUE,4037,TEST,DP
318,9845,4928400,Time for return to daily activities,Transperitoneal laparoscopic ureterolithotomy,Flexible ureteroscopy,significantly increased,1,continuous,,22,,20,13.3,1.7,9,1.6,2.5595,0.1734,,,,,,FALSE,TRUE,FALSE,TRUE,4037,TEST,DP
319,4723,5539943,reflections of sustain talk,Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),significantly decreased,-1,continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,TEST,DP
320,4724,5539943,"""sustain talk"" (ST)",Language Enhanced Attention and Focus MI training condition (MI-LEAF),baseline,significantly decreased,-1,continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,TEST,DP
321,4725,5539943,"Frequency of client ""change talk"" (CT)",Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),no significant difference,0,continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,TEST,DP
322,4726,5539943,Motivational Interviewing (MI) knowledge,Language Enhanced Attention and Focus MI training condition (MI-LEAF),baseline,significantly increased,1,continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,TEST,DP
323,4726,5539943,Motivational Interviewing (MI) knowledge,MI training (MI-AU),baseline,significantly increased,1,continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,TEST,DP
324,4727,5539943,Motivational Interviewing (MI) knowledge,Language Enhanced Attention and Focus MI training condition (MI-LEAF),MI training (MI-AU),significantly increased,1,continuous,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,No group sizes and individual means and stds given,FALSE,FALSE,FALSE,FALSE,9850,TEST,DP
325,5372,5559992,Anxiety,Buprenophine 32 mg,No treatment,significantly decreased,-1,continuous,,5,,5,1,2.23,11,8.63,-1.4322,0.5026,,,,,"decided ""no treatment"" meant baseline",FALSE,TRUE,TRUE,TRUE,1146,TEST,DP
326,5373,5559992,Anxiety,Buprenophine 64 mg,No treatment,significantly decreased,-1,continuous,,4,,4,1.25,2.5,26.5,14.7,-2.0802,0.7704,,,,,"decided ""no treatment"" meant baseline",FALSE,TRUE,TRUE,TRUE,1146,TEST,DP
327,5374,5559992,Anxiety,Buprenophine 96 mg,No treatment,significantly decreased,-1,continuous,,5,,5,0,0,23.8,13.82,-2.1985,0.6417,,,,,"decided ""no treatment"" meant baseline",FALSE,TRUE,TRUE,TRUE,1146,TEST,DP
328,5375,5559992,Anxiety,Buprenophine 32 mg,Buprenophine 64 mg,no significant difference,0,continuous,,5,,4,1,2.23,1.25,2.5,-0.0945,0.4505,,,,,found in table,FALSE,TRUE,TRUE,TRUE,1146,TEST,DP
329,5376,5559992,Anxiety,Buprenophine 32 mg,Buprenophine 96 mg,no significant difference,0,continuous,,5,,5,1,2.23,0,0,0.5725,0.4164,,,,,found in table,FALSE,TRUE,TRUE,TRUE,1146,TEST,DP
330,5377,5559992,Anxiety,Buprenophine 64 mg,Buprenophine 96 mg,no significant difference,0,continuous,,4,,5,1.25,2.5,0,0,0.6784,0.4756,,,,,found in table,FALSE,TRUE,TRUE,TRUE,1146,TEST,DP
331,5078,5617873,Parent-rated Aberrant Behavior Checklis improvement,Aripiprazole,Placbeo,significantly increased,1,continuous,,45,,47,-11.4,1.3,-7.5,1.4,-2.8604,0.088,,,,,"all means and std found in table 2, given as mean change from baseline",FALSE,TRUE,FALSE,TRUE,7551,TEST,DP
332,5079,5617873,Clinician-rated Clinical Global Impression-Improvement scores,Aripiprazole,Placbeo,significantly increased,1,continuous,,,,,2.4,0.1,3.4,0.1,-9.9164,0.5779,,,,,raw values foun din text,FALSE,FALSE,FALSE,TRUE,7551,TEST,DP
333,5080,5617873,Serious adverse effects,Aripiprazole,Placbeo,no significant difference,0,binary,0,45,3,47,,,,,,,-1.9681,2.3302,-1.9034,2.2431,all means and std found in table 2,FALSE,TRUE,FALSE,TRUE,7551,TEST,DP
334,5081,5617873,Inappropriate speech,Aripiprazole,Placbeo,no significant difference,0,continuous,,45,,47,-2.2,0.4,-1.5,0.4,-1.7354,0.0599,,,,,"table 2, given as mean change",FALSE,TRUE,FALSE,TRUE,7551,TEST,DP
335,5082,5617873,Social withdrawal,Aripiprazole,Placbeo,no significant difference,0,continuous,,45,,47,-4.7,1.1,-5.2,1,0.4722,0.0447,,,,,"table 2, given as mean change",FALSE,TRUE,FALSE,TRUE,7551,TEST,DP
336,5083,5617873,Compulsion scale,Aripiprazole,Placbeo,no significant difference,0,continuous,,45,,47,-1.3,0.5,-2,0.5,1.3883,0.054,,,,,"table 2, given as mean change",FALSE,TRUE,FALSE,TRUE,7551,TEST,DP
337,11078,5655920,Nausea,Lixisenatide with normal renal function,Lixisenatide with mild impairment,significantly decreased,-1,binary,,2094,,637,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = -0.1,FALSE,TRUE,FALSE,TRUE,13081,TEST,DP
338,11078,5655920,vomiting,Lixisenatide with normal renal function,Lixisenatide with mild impairment,significantly decreased,-1,binary,,2094,,637,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = -0.1,FALSE,TRUE,FALSE,TRUE,13081,TEST,DP
339,11079,5655920,Nausea,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,no significant difference,0,binary,,122,,637,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = 0.04,FALSE,TRUE,FALSE,TRUE,13081,TEST,DP
340,11079,5655920,vomiting,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,no significant difference,0,binary,,122,,637,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = 0.04,FALSE,TRUE,FALSE,TRUE,13081,TEST,DP
341,11080,5655920,Nausea,Lixisenatide with moderate impairment,Lixisenatide with normal renal function,no significant difference,0,binary,,122,,2094,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = -0.03,FALSE,TRUE,FALSE,TRUE,13081,TEST,DP
342,11080,5655920,vomiting,Lixisenatide with moderate impairment,Lixisenatide with normal renal function,no significant difference,0,binary,,122,,2094,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = -0.03,FALSE,TRUE,FALSE,TRUE,13081,TEST,DP
343,11081,5655920,Hypoglycaemia,Lixisenatide with normal renal function,Lixisenatide with mild impairment,no significant difference,0,binary,,2094,,637,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = -0.02,FALSE,TRUE,FALSE,TRUE,13081,TEST,DP
344,11082,5655920,Hypoglycaemia,Lixisenatide with moderate impairment,Lixisenatide with mild impairment,no significant difference,0,binary,,122,,637,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,placebo-adjusted meta-analysis (fixed effect) = 0.04,FALSE,TRUE,FALSE,TRUE,13081,TEST,DP
345,10232,5686687,Pain,Resveratrol,Placebo,no significant difference,0,continuous,,22,,22,,,,,cannot calculate,cannot calculate,,,,,given as median and range,FALSE,TRUE,FALSE,FALSE,7451,TEST,DP
346,10233,5686687,Need for dipyrone,Resveratrol,Placebo,no significant difference,0,continuous,,22,,22,1944,1793,625,250,1.0119,0.1025,,,,,found in table,FALSE,TRUE,FALSE,TRUE,7451,TEST,DP
347,10234,5686687,Need for Ibuprofen,Resveratrol,Placebo,no significant difference,0,continuous,,22,,22,1200,848,5640,328,-6.7818,0.6136,,,,,found in table,FALSE,TRUE,FALSE,TRUE,7451,TEST,DP
348,10235,5686687,Prolactin levels,Resveratrol,Placebo,no significant difference,0,continuous,,22,,22,,,,,cannot calculate,cannot calculate,,,,,median and ranges given,FALSE,TRUE,FALSE,FALSE,7451,TEST,DP
349,10236,5686687,CA-125 levels,Resveratrol,Placebo,no significant difference,0,continuous,,22,,22,,,,,cannot calculate,cannot calculate,,,,,median and ranges given,FALSE,TRUE,FALSE,FALSE,7451,TEST,DP
350,4493,5874317,Knee extension (1-rep Max),Bilateral training,Unilateral training,no significant difference,0,continuous,,9,,9,237.2,51,182.4,8.4,1.4252,0.2786,,,,,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,TEST,DP
351,4494,5874317,Knee flexion (1-rep Max),Bilateral training,Unilateral training,significantly increased,1,continuous,,9,,9,99.8,10.2,86.8,2.9,1.6509,0.2979,,,,,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,TEST,DP
352,4495,5874317,Change of direction improvement,Bilateral training,Unilateral training,no significant difference,0,continuous,,9,,9,5.46,0.2,5.67,0.16,-1.1042,0.2561,,,,,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,TEST,DP
353,4496,5874317,Squat jump,Bilateral training,Unilateral training,significantly increased,1,continuous,,9,,9,0.37,0.04,0.34,0.04,0.7142,0.2364,,,,,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,TEST,DP
354,4497,5874317,Horizontal countermovement jump,Bilateral training,Unilateral training,significantly increased,1,continuous,,9,,9,2.34,0.07,2.21,0.15,1.0576,0.2533,,,,,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,TEST,DP
355,4498,5874317,Horizontal triple jump (non-dominant leg),Bilateral training,Unilateral training,significantly decreased,-1,continuous,,9,,9,5.71,0.71,5.7,0.45,0.016,0.2222,,,,,Found in table raw values,FALSE,TRUE,FALSE,TRUE,10785,TEST,DP
356,4710,5884950,objective-SCORAD score,extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,no significant difference,0,continuous,,13,,13,,,,,cannot calculate,cannot calculate,,,,,"mean and std not given, only median and interquartile range",FALSE,FALSE,FALSE,FALSE,11712,TEST,DP
357,4711,5884950,chemokines CXCL9,extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).,significantly increased,1,continuous,,13,,13,,,,,cannot calculate,cannot calculate,,,,,"mean and std not given, only median and interquartile range",FALSE,FALSE,FALSE,FALSE,11712,TEST,DP
358,8710,5971365,clinically meaningful improvement at week 144 (⩾3-point increase on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,significantly increased,1,binary,188,287,144,277,,,,,,,0.5619,0.0299,0.2312,0.0052,"counts calculated from percentages given in text, totals found in figure",FALSE,FALSE,FALSE,TRUE,3177,TEST,DP
359,8711,5971365,Symbol Digit Modalities Test (SDMT) score at week 96,daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,significantly increased,1,continuous,,720,,682,4.1,12.4,2.9,12.7,0.0956,0.0029,,,,,"found in figure and text, totals found in figure",TRUE,FALSE,FALSE,TRUE,3177,TEST,DP
360,8712,5971365,Symbol Digit Modalities Test (SDMT) score at week 144 in limited patients,daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,significantly increased,1,continuous,,287,,277,6.3,12.6,3.1,13.2,0.2478,0.0071,,,,,"found in figure and text, totals found in figure",FALSE,FALSE,FALSE,TRUE,3177,TEST,DP
361,8713,5971365,clinically meaningful worsening at week 96 (⩾3-point decrease on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,significantly decreased,-1,binary,140,720,169,682,,,,,,,-0.311,0.0167,-0.2425,0.0102,"counts calculated from percentages given in text, totals found in figure",TRUE,FALSE,FALSE,TRUE,3177,TEST,DP
362,8714,5971365,clinically meaningful improvement at week 96 (⩾3-point increase on the SDMT),daclizumab beta,intramuscular (IM) interferon (IFN) beta-1a,significantly increased,1,binary,432,720,369,682,,,,,,,0.2409,0.0117,0.1034,0.0022,"counts calculated from percentages given in text, totals found in figure",TRUE,FALSE,FALSE,TRUE,3177,TEST,DP
363,12884,5976949,ANGPTL4 expression,"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)",control group- normal glucose tolerance,significantly decreased,-1,continuous,,20,,25,23.1,25.6,98.3,104.6,-0.9238,0.0995,,,,,found in table,FALSE,TRUE,FALSE,TRUE,4402,TEST,DP
364,12885,5976949,ANGPTL4 expression,"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)","GDM2 (less tight glycaemic targets, <5.3_mmol/L and <_7.8_mmol/L)",no significant difference,0,continuous,,20,,21,23.1,25.6,21.5,25.8,0.061,0.0977,,,,,found in table,FALSE,TRUE,FALSE,TRUE,4402,TEST,DP
365,12886,5976949,leptin/adiponectin ratio (LAR),"GDM2 (less tight glycaemic targets, <5.3 mmol/L and < 7.8 mmol/L)","GDM1 (tight glycaemic targets, fasting blood glucose_<_5.1_mmol/L and <7.0_mmol/L postprandial) postprandial,), control group- normal glucose tolerance",significantly increased,1,continuous,,21,,45,1.7,1.66,,,cannot calculate,cannot calculate,,,,,combined means and stds not given,FALSE,TRUE,FALSE,FALSE,4402,TEST,DP
366,12887,5976949,leptin/adiponectin ratio (LAR),"GDM1 (tight glycaemic targets, fasting blood glucose < 5.1 mmol/L and <7.0 mmol/L postprandial)",control group- normal glucose tolerance,no significant difference,0,continuous,,20,,25,0.97,1.31,0.72,0.46,0.2624,0.0908,,,,,found in table,FALSE,TRUE,FALSE,TRUE,4402,TEST,DP
367,224,1475568,Minnesota living with heart failure (MLHF) questionnaire baseline scores,Follow-up and thorough education on self-care,Standard information about self-care,significantly decreased,-1,continuous,,59,,64,45,,57,,cannot calculate,cannot calculate,,,,,Only the mean score was given in table.,FALSE,TRUE,FALSE,FALSE,"4,361",TEST,HY
368,216,1475568,Heart failure-related quality of life at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,no significant difference,0,continuous,,59,,64,1,,5,,cannot calculate,cannot calculate,,,,,Only the mean change was found in text.,FALSE,FALSE,FALSE,FALSE,"4,361",TEST,HY
369,217,1475568,Baseline hypertension,Follow-up and thorough education on self-care,Standard information about self-care,no significant difference,0,binary,51,59,57,64,,,,,,,-0.2448,0.305,-0.0299,0.0046,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,"4,361",TEST,HY
370,218,1475568,Baseline diabetes,Follow-up and thorough education on self-care,Standard information about self-care,no significant difference,0,binary,35,59,33,64,,,,,,,0.3148,0.1328,0.1402,0.0263,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,"4,361",TEST,HY
371,228,1475568,Baseline life-quality score,Follow-up and thorough education on self-care,Standard information about self-care,significantly decreased,-1,continuous,,59,,64,45,,57,,cannot calculate,cannot calculate,,,,,Only the mean score was given in table.,FALSE,TRUE,FALSE,FALSE,"4,361",TEST,HY
372,226,1475568,Knowledge about heart failure,Follow-up and thorough education on self-care,Standard information about self-care,significantly increased,1,continuous,,59,,64,,,,,cannot calculate,cannot calculate,,,,,Only the overall mean difference in score improvement was given.,FALSE,FALSE,FALSE,FALSE,"4,361",TEST,HY
373,220,1475568,Baseline beta-blockers intake,Follow-up and thorough education on self-care,Standard information about self-care,no significant difference,0,binary,32,59,46,64,,,,,,,-0.7684,0.1456,-0.2816,0.0204,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,"4,361",TEST,HY
374,227,1475568,Self-efficacy,Follow-up and thorough education on self-care,Standard information about self-care,significantly increased,1,continuous,,59,,64,,,,,cannot calculate,cannot calculate,,,,,Only the overall mean difference in score improvement was given.,FALSE,FALSE,FALSE,FALSE,"4,361",TEST,HY
375,219,1475568,Baseline systolic dysfunction,Follow-up and thorough education on self-care,Standard information about self-care,no significant difference,0,binary,23,59,28,64,,,,,,,-0.1967,0.1347,-0.1154,0.0466,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,"4,361",TEST,HY
376,223,1475568,Baseline angiotensin II receptor blockers (ARBs) intake,Follow-up and thorough education on self-care,Standard information about self-care,no significant difference,0,binary,,59,,64,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Unclear since the values for this are reported with ACEI intake.,FALSE,TRUE,FALSE,FALSE,"4,361",TEST,HY
377,222,1475568,Baseline digoxin intake,Follow-up and thorough education on self-care,Standard information about self-care,no significant difference,0,binary,15,59,12,64,,,,,,,0.3902,0.192,0.3045,0.1174,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,"4,361",TEST,HY
378,221,1475568,Baseline angiotensin-converting enzyme (ACE) inhibitors intake,Follow-up and thorough education on self-care,Standard information about self-care,no significant difference,0,binary,,59,,64,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Unclear since the values for this are reported with ARB intake.,FALSE,TRUE,FALSE,FALSE,"4,361",TEST,HY
379,214,1475568,Hospitalization or death,Follow-up and thorough education on self-care,Standard information about self-care,no significant difference,0,binary,25,59,39,64,,,,,,,-0.7522,0.1351,-0.3633,0.0331,Used percentage found in table to calculate actual number for binary variable.,FALSE,TRUE,FALSE,TRUE,"4,361",TEST,HY
380,215,1475568,Daily weight monitoring at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,significantly increased,1,binary,47,59,19,64,,,,,,,2.2275,0.1795,0.9871,0.0413,Used percentage found in text to calculate actual number for binary variable.,FALSE,FALSE,FALSE,TRUE,"4,361",TEST,HY
381,225,1475568,Cardiac-related hospitalization,Follow-up and thorough education on self-care,Standard information about self-care,no significant difference,0,binary,20,59,25,64,,,,,,,-0.2231,0.1413,-0.1418,0.0574,Used percentage found in text to calculate actual number for binary variable.,FALSE,FALSE,FALSE,TRUE,"4,361",TEST,HY
382,876,2974815,discontinued treatment,"""phone calls"" group","""no phone calls"" group",significantly decreased,-1,binary,4,108,30,246,,,,,,,-1.284,0.2976,-1.1917,0.27,Values from results section text.,FALSE,FALSE,FALSE,TRUE,"13,659",TEST,HY
383,949,3278655,maximum total point motion (MTPM),The trabecular metal tibial monoblock component (TM),cemented component.,no significant difference,0,continuous,,27,,18,0.98,3.91,0.79,2.27,0.0556,0.0926,,,,,Back calculated the SD values from CI. Numerical values are from 5-year follow up.,FALSE,TRUE,FALSE,TRUE,"5,463",TEST,HY
384,877,2974815,The percentage of patients with controlled blood pressure (<140/90 mmHg),"""phone calls"" group","""no phone calls"" group",no significant difference,0,binary,,108,,246,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Numerical values are not available.,FALSE,FALSE,FALSE,FALSE,"13,659",TEST,HY
385,1118,3577738,website use in terms of the number of pages visited,website with social presence elements.,website without social presence elements.,no significant difference,0,continuous,,,,,7.5,4,8,3.8,cannot calculate,cannot calculate,,,,,Cannot find the group sizes in the text or table.,FALSE,TRUE,FALSE,FALSE,"3,018",TEST,HY
386,1118,3577738,website use in terms of time on the website,website with social presence elements.,website without social presence elements.,no significant difference,0,continuous,,,,,151,117.4,150.8,107.8,cannot calculate,cannot calculate,,,,,Cannot find the group sizes in the text or table.,FALSE,TRUE,FALSE,FALSE,"3,018",TEST,HY
387,1119,3577738,focused on the social presence elements in terms of frequency,website with social presence elements.,website without social presence elements.,significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,"3,018",TEST,HY
388,1119,3577738,focused on the social presence elements in terms of duration,website with social presence elements.,website without social presence elements.,significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,"3,018",TEST,HY
389,875,2974815,percentage of patients with controlled blood pressure,"""phone calls"" group","""no phone calls"" group",no significant difference,0,binary,86,108,175,246,,,,,,,0.4612,0.0769,0.1128,0.004,"Used 80% for ""phone calls"" group and 71% for ""no phone calls"" group.",FALSE,FALSE,FALSE,TRUE,"13,659",TEST,HY
390,950,3278655,subsidence,The trabecular metal tibial monoblock component (TM),cemented component.,significantly increased,1,continuous,,27,,18,-0.38,0.37,-0.04,0.11,-1.1288,0.1068,,,,,Used numerical values for Superior/inferior translation (SD). Numerical values are from 5-year follow up.,FALSE,TRUE,FALSE,TRUE,"5,463",TEST,HY
391,951,3278655,"The proportion of ""at risk"" components at 5 years",The trabecular metal tibial monoblock component (TM),cemented component.,no significant difference,0,binary,0,27,2,18,,,,,,,-2.1203,2.497,-1.9972,2.3117,Used numerical values from 5-year follow up provided in abstract.,FALSE,FALSE,FALSE,TRUE,"5,463",TEST,HY
392,1120,3577738,efficiency,website with social presence elements.,website without social presence elements.,no significant difference,0,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,"3,018",TEST,HY
393,1120,3577738,effectiveness,website with social presence elements.,website without social presence elements.,no significant difference,0,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,"3,018",TEST,HY
394,1120,3577738,enjoyment,website with social presence elements.,website without social presence elements.,no significant difference,0,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,"3,018",TEST,HY
395,1120,3577738,active trust,website with social presence elements.,website without social presence elements.,no significant difference,0,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,"3,018",TEST,HY
396,1120,3577738,interest,website with social presence elements.,website without social presence elements.,no significant difference,0,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Cannot find the group sizes in the text or table. Also, no numerical values for this outcome is found for each of the conditions.",FALSE,FALSE,FALSE,FALSE,"3,018",TEST,HY
397,2240,4678179,progression-free-survival (PFS),vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),no significant difference,0,continuous,,53,,53,,,,,cannot calculate,cannot calculate,,,,,Median was only given.,FALSE,FALSE,FALSE,FALSE,"9,517",TEST,HY
398,2241,4678179,Median overall survival (OS),vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),no significant difference,0,continuous,,53,,53,6.9,4.09,6.1,5.57,0.1625371,0.03786046,,,,,"Median is given with CI. Since the outcome explicitly says ""median"", including median values. Back calculated SD using CI.",FALSE,FALSE,FALSE,TRUE,"9,517",TEST,HY
399,2242,4678179,Response rates,vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),no significant difference,0,continuous,,53,,53,8,,13,,cannot calculate,cannot calculate,,,,,Only difference in response rates as percent is given.,FALSE,FALSE,FALSE,FALSE,"9,517",TEST,HY
400,2243,4678179,rate of adverse events,vismodegib plus gemcitabine (GV),gemcitabine plus placebo (GP),no significant difference,0,binary,4,53,2,53,,,,,,,0.73315252,0.79001601,0.69314718,0.71226415,Used numbers found in results section text.,FALSE,FALSE,FALSE,TRUE,"9,517",TEST,HY
401,2723,5268424,score on the general dimension scale of negative affects (referred to as NA from here onward),view a video featuring individuals that live in extreme poverty,control,significantly increased,1,continuous,,55,,50,21.036,6.327,17.68,5.859,0.5453569,0.03959808,,,,,,FALSE,TRUE,FALSE,TRUE,"12,258",TEST,HY
402,2804,5781260,Exercise-induced Creatine kinase (CK),lemon verbena extract,placebo,no significant difference,0,continuous,,20,,20,,,,,cannot calculate,cannot calculate,,,,,Mean and CI in figure.,TRUE,FALSE,FALSE,FALSE,"4,385",TEST,HY
403,2802,5781260,exercise-related loss of muscle strength,lemon verbena extract,placebo,significantly decreased,-1,continuous,,20,,20,,,,,cannot calculate,cannot calculate,,,,,Mean and CI in figure.,TRUE,FALSE,FALSE,FALSE,"4,385",TEST,HY
404,2805,5781260,Glutathione peroxidase (GPxP),lemon verbena extract,placebo,no significant difference,0,continuous,,20,,20,,,,,cannot calculate,cannot calculate,,,,,Mean and CI in figure.,TRUE,FALSE,FALSE,FALSE,"4,385",TEST,HY
405,2807,5781260,adverse events,lemon verbena extract,placebo,no significant difference,0,binary,,20,,20,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Unclear numerical values.,FALSE,FALSE,FALSE,FALSE,"4,385",TEST,HY
406,2803,5781260,Movement induced pain (VAS),lemon verbena extract,placebo,no significant difference,0,continuous,,20,,20,,,,,cannot calculate,cannot calculate,,,,,Mean and CI in figure.,FALSE,FALSE,FALSE,FALSE,"4,385",TEST,HY
407,2806,5781260,Interleukin 6,lemon verbena extract,placebo,no significant difference,0,continuous,,20,,20,,,,,cannot calculate,cannot calculate,,,,,Numerical values are not given.,FALSE,FALSE,FALSE,FALSE,"4,385",TEST,HY
408,3260,3475525,Correct selection of the healthier product,MTL+caloric intake group,No label group,significantly increased,1,continuous,,90,,99,73.3,6.9,67.8,10.3,0.61923041,0.02222653,,,,,Available in abstract and table,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
409,3260,3475525,Correct selection of the healthier product,MTL+caloric intake group,TL+SNL group,significantly increased,1,continuous,,90,,95,73.3,6.9,65.8,7.3,1.05077696,0.02462157,,,,,Available in abstract and table,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
410,3260,3475525,Correct selection of the healthier product,choices group,No label group,significantly increased,1,continuous,,98,,99,72.5,13.2,67.8,10.3,0.3957062,0.02070251,,,,,Available in abstract and table,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
411,3260,3475525,Correct selection of the healthier product,choices group,TL+SNL group,significantly increased,1,continuous,,98,,95,72.5,13.2,65.8,7.3,0.62309408,0.02173622,,,,,Available in abstract and table,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
412,3262,3475525,Taste perception,MTL group,No label group,no significant difference,0,continuous,,98,,99,5.6,1.4,5.8,1.4,-0.1423069,0.02035649,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
413,3262,3475525,Taste perception,MTL+caloric intake group,No label group,no significant difference,0,continuous,,90,,99,5.4,1.4,5.8,1.4,-0.2845666,0.02142635,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
414,3262,3475525,Taste perception,MTL group,choices group,no significant difference,0,continuous,,98,,98,5.6,1.4,5.3,1.5,0.20597307,0.02051639,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
415,3262,3475525,Taste perception,MTL+caloric intake group,choices group,no significant difference,0,continuous,,90,,98,5.4,1.4,5.3,1.5,0.06854473,0.02132769,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
416,3262,3475525,intent of purchase,MTL group,No label group,no significant difference,0,continuous,,98,,99,3.8,1.4,4.1,1.5,-0.2059408,0.02041274,,,,,Used values for self.,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
417,3262,3475525,intent of purchase,MTL+caloric intake group,No label group,no significant difference,0,continuous,,90,,99,3.6,1.4,4.1,1.5,-0.3426709,0.02152276,,,,,Used values for self.,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
418,3262,3475525,intent of purchase,MTL group,choices group,no significant difference,0,continuous,,98,,98,3.8,1.4,4.1,1.7,-0.1919025,0.02050211,,,,,Used values for self.,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
419,3262,3475525,intent of purchase,MTL+caloric intake group,choices group,no significant difference,0,continuous,,90,,98,3.6,1.5,4.1,1.7,-0.3098034,0.02157045,,,,,Used values for self.,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
420,3401,3877023,quantitative contour sharpness of the Cervicothoracic Spine,short-bore MR scanner,high-field horizontal open MR scanner,significantly increased,1,continuous,,18,,21,0.95,0.24,1.43,0.48,-1.2099846,0.12194464,,,,,"Original outcome was ""quantitative contour sharpness"".",FALSE,FALSE,FALSE,TRUE,"17,694",TEST,HY
421,3401,3877023,quantitative contour sharpness of the thoracolumbar spine,short-bore MR scanner,high-field horizontal open MR scanner,significantly increased,1,continuous,,30,,34,0.83,0.22,1.32,0.51,-1.2060514,0.07410885,,,,,"Original outcome was ""quantitative contour sharpness"".",FALSE,FALSE,FALSE,TRUE,"17,694",TEST,HY
422,3402,3877023,contrast-to-noise ratios (CNR) of Cervicothoracic Spine - T2w sagittal Cerebrospinal fluid – Spinal cord,short-bore MR scanner,high-field horizontal open MR scanner,significantly increased,1,continuous,,18,,21,18.1,11.6,9.3,5.5,0.97494517,0.11536073,,,,,,FALSE,TRUE,FALSE,TRUE,"17,694",TEST,HY
423,3402,3877023,contrast-to-noise ratios (CNR) of Thoracolumbar Spine - T2w sagittal Cerebrospinal fluid – Spinal cord,short-bore MR scanner,high-field horizontal open MR scanner,significantly increased,1,continuous,,30,,34,22.3,13.2,14,5.6,0.8274306,0.06809386,,,,,,FALSE,TRUE,FALSE,TRUE,"17,694",TEST,HY
424,3402,3877023,contrast-to-noise ratios (CNR) of Cervicothoracic Spine - T2w sagittal Cerebrospinal fluid – Vertebral bone,short-bore MR scanner,high-field horizontal open MR scanner,significantly increased,1,continuous,,18,,21,19.3,10.3,8.2,5.7,1.33530568,0.12603411,,,,,,FALSE,TRUE,FALSE,TRUE,"17,694",TEST,HY
425,3402,3877023,contrast-to-noise ratios (CNR) of Thoracolumbar Spine - T2w sagittal Cerebrospinal fluid – Vertebral bone,short-bore MR scanner,high-field horizontal open MR scanner,significantly increased,1,continuous,,30,,34,24,12.9,11.7,6.3,1.22140465,0.07440001,,,,,,FALSE,TRUE,FALSE,TRUE,"17,694",TEST,HY
426,3403,3877023,Scanning times,high-field horizontal open MR scanner,short-bore MR scanner,significantly increased,1,continuous,,49,,44,32,22,20,9,0.69457406,0.04572916,,,,,,FALSE,FALSE,FALSE,TRUE,"17,694",TEST,HY
427,3404,3877023,The mean signal-to-noise (SNR) values,short-bore MR scanner,high-field horizontal open MR scanner,significantly increased,1,continuous,,44,,49,17.97,6.58,11.28,4.35,1.20253898,0.05091017,,,,,,FALSE,FALSE,FALSE,TRUE,"17,694",TEST,HY
428,3261,3475525,Scores on the saturated fat quiz,MTL group,No label group,significantly increased,1,continuous,,98,,99,90.7,20.4,33.6,16.3,3.08231109,0.0444184,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
429,3261,3475525,Scores on the saturated fat quiz,MTL+caloric intake group,No label group,significantly increased,1,continuous,,90,,99,92.3,15.1,33.6,16.3,3.71430281,0.0577096,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
430,3261,3475525,Scores on the saturated fat quiz,MTL group,choices group,significantly increased,1,continuous,,98,,98,90.7,20.4,35.7,15.9,2.99563986,0.04330066,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
431,3261,3475525,Scores on the saturated fat quiz,MTL+caloric intake group,choices group,significantly increased,1,continuous,,90,,98,92.3,15.1,35.7,15.9,3.63162908,0.0563916,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
432,3261,3475525,Scores on sugar quiz,MTL group,No label group,significantly increased,1,continuous,,98,,99,90,20.7,47.2,19.6,2.11539588,0.03166271,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
433,3261,3475525,Scores on sugar quiz,MTL+caloric intake group,No label group,significantly increased,1,continuous,,90,,99,92.6,15.5,47.2,19.6,2.54502741,0.03834748,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
434,3261,3475525,Scores on sugar quiz,MTL group,choices group,significantly increased,1,continuous,,98,,98,90,20.7,41.9,19.4,2.38845924,0.03496107,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
435,3261,3475525,Scores on sugar quiz,MTL+caloric intake group,choices group,significantly increased,1,continuous,,90,,98,92.6,15.5,41.9,19.4,2.86225472,0.04310376,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
436,3261,3475525,Scores on sodium quiz,MTL group,No label group,significantly increased,1,continuous,,98,,99,93.5,16.4,42.6,20.7,2.71359845,0.03899447,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
437,3261,3475525,Scores on sodium quiz,MTL+caloric intake group,No label group,significantly increased,1,continuous,,90,,99,94.1,15.6,42.6,20.7,2.78020714,0.04166067,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
438,3261,3475525,Scores on sodium quiz,MTL group,choices group,significantly increased,1,continuous,,98,,98,93.5,16.4,47.1,21.1,2.44594908,0.03567007,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
439,3261,3475525,Scores on sodium quiz,MTL+caloric intake group,choices group,significantly increased,1,continuous,,90,,98,94.1,15.6,47.1,21.1,2.50703599,0.03803123,,,,,,FALSE,TRUE,FALSE,TRUE,"9,086",TEST,HY
440,8803,4467620,decrease in exercise intensity as time elapsed (at time 10),Hot + Cooling conditions,Hot conditions,no significant difference,0,continuous,,8,,8,114.6,35.6,123.9,30.2,-0.2663137,0.25221634,,,,,Added the last timepoint to the outcome name. Since there are 10 different time points.,FALSE,TRUE,FALSE,TRUE,"7,288",TEST,HY
441,8804,4467620,weight reduction,Hot + Cooling conditions,Hot conditions,no significant difference,0,continuous,,8,,8,68.6,7.7,68.8,7.5,-0.0248738,0.25001933,,,,,The numerical values are from Exercise state.,FALSE,TRUE,FALSE,TRUE,"7,288",TEST,HY
442,8805,4467620,accuracy of the cognitive tasks,Exercise - Hot + Cooling conditions,At rest - Hot + Cooling conditions,significantly decreased,-1,continuous,,8,,8,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,FALSE,FALSE,"7,288",TEST,HY
443,8801,4467620,accuracy of the cognitive tasks,Exercise - Hot condition,At rest - Hot condition,significantly decreased,-1,continuous,,8,,8,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,FALSE,FALSE,"7,288",TEST,HY
444,8802,4467620,differences in the accuracy,Hot + Cooling conditions,Hot conditions,no significant difference,0,continuous,,8,,8,,,,,cannot calculate,cannot calculate,,,,,,TRUE,FALSE,FALSE,FALSE,"7,288",TEST,HY
445,4098,4140238,ocular itching for visit 3B at 7 min,bepotastine besilate ophthalmic solution (BBOS) 1.5%,placebo,significantly decreased,-1,continuous,,70,,70,1.2,,2.1,,cannot calculate,cannot calculate,,,,,"Original outcome name is ""ocular itching"". However, due to many different visits and data from timepoints. We specified this in the outcome. Visit 3B was the first study they conducted and 7 min is the last timepoint. No SD information was given",FALSE,TRUE,FALSE,FALSE,"12,685",TEST,HY
446,4002,4879328,waist circumference,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,no significant difference,0,continuous,,104,,114,-0.89,3.32,0.3,3.54,-0.3450435,0.01866038,,,,,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,"12,872",TEST,HY
447,4003,4879328,effects for walking,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,no significant difference,0,continuous,,104,,114,-0.55,2.29,0.31,3.84,-0.2681458,0.01855223,,,,,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,"12,872",TEST,HY
448,4003,4879328,effects for vigorous activity,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,no significant difference,0,continuous,,104,,114,0.2,1.56,-0.4,2.48,0.28575833,0.0185746,,,,,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,"12,872",TEST,HY
449,4004,4879328,FFBQ Total Index Score,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,significantly increased,1,continuous,,104,,114,0.07,0.26,0.01,0.33,0.20018961,0.01847923,,,,,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,"12,872",TEST,HY
450,4005,4879328,weekly moderate physical activity sessions,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,significantly increased,1,continuous,,104,,114,0.19,1.82,-0.68,2.32,0.41353429,0.01877954,,,,,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,"12,872",TEST,HY
451,4006,4879328,accelerometer-assessed moderate to vigorous physical activity (MVPA),"Get Healthy, Stay Healthy' (GHSH)",no continued contact,significantly increased,1,continuous,,99,,108,7.41,66.12,-16.1,66.25,0.35389959,0.01966279,,,,,Values are from Accelerometer PA in Table 2. Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,"12,872",TEST,HY
452,4001,4879328,weight loss,"Get Healthy, Stay Healthy' (GHSH)",no continued contact,significantly increased,1,continuous,,104,,114,-0.89,3.33,0.3,3.54,-0.3445812,0.01865965,,,,,Back calculated SD using CI.,FALSE,TRUE,FALSE,TRUE,"12,872",TEST,HY
453,4432,5726464,Glucose,Vitamin D plus calcium supplementation,Placebo,no significant difference,0,continuous,,79,,86,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,"6,563",TEST,HY
454,4432,5726464,insulin,Vitamin D plus calcium supplementation,Placebo,no significant difference,0,continuous,,79,,86,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,"6,563",TEST,HY
455,4422,4483334,Amount of calcium and phosphate on enamel surface,CPP-ACP plus laser (group D),Distilled and deionized water (group A),significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Original outcome was ""Amount of calcium and phosphate on enamel surface"" but changed to ""Total weight percentage of calcium"" since this seemed more accurate. All numerical values are in a graphical format of table.",FALSE,TRUE,TRUE,FALSE,"1,396",TEST,HY
456,4423,4483334,Total weight percentage of calcium,CPP-ACP plus laser (group D),Nd:YAG laser (group B),significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Original outcome was ""Amount of calcium and phosphate on enamel surface"" but changed to ""Total weight percentage of calcium"" since this seemed more accurate. All numerical values are in a graphical format of table.",FALSE,TRUE,TRUE,FALSE,"1,396",TEST,HY
457,4424,4483334,Total weight percentage of calcium,CPP-ACP plus laser (group D),CPP-ACP crème (group C),significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,"Original outcome was ""Amount of calcium and phosphate on enamel surface"" but changed to ""Total weight percentage of calcium"" since this seemed more accurate. All numerical values are in a graphical format of table.",FALSE,TRUE,TRUE,FALSE,"1,396",TEST,HY
458,4425,4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),Distilled and deionized water (group A),significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,All numerical values are in a graphical format of table.,FALSE,TRUE,TRUE,FALSE,"1,396",TEST,HY
459,4425,4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),Nd:YAG laser (group B),significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,All numerical values are in a graphical format of table.,FALSE,TRUE,TRUE,FALSE,"1,396",TEST,HY
460,4425,4483334,Total weight percentage of phosphate,CPP-ACP plus laser (group D),CPP-ACP crème (group C),significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,All numerical values are in a graphical format of table.,FALSE,TRUE,TRUE,FALSE,"1,396",TEST,HY
461,4430,5726464,25(OH)D levels,Vitamin D plus calcium supplementation,Placebo,significantly increased,1,continuous,,79,,86,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,"6,563",TEST,HY
462,4431,5726464,Lipid profile: total cholesterol,Vitamin D plus calcium supplementation,Placebo,no significant difference,0,continuous,,79,,86,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,"6,563",TEST,HY
463,4431,5726464,Lipid profile: HDL-c,Vitamin D plus calcium supplementation,Placebo,no significant difference,0,continuous,,79,,86,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,"6,563",TEST,HY
464,4431,5726464,Lipid profile: LDL-c,Vitamin D plus calcium supplementation,Placebo,no significant difference,0,continuous,,79,,86,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,"6,563",TEST,HY
465,4431,5726464,Lipid profile: Triglycerides,Vitamin D plus calcium supplementation,Placebo,no significant difference,0,continuous,,79,,86,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,"6,563",TEST,HY
466,4433,5726464,Changes in body mass index,Vitamin D plus calcium supplementation,Placebo,no significant difference,0,continuous,,79,,86,,,,,cannot calculate,cannot calculate,,,,,Median was reported.,FALSE,TRUE,FALSE,FALSE,"6,563",TEST,HY
467,4434,5726464,Metabolic syndrome,Vitamin D plus calcium supplementation,Placebo,no significant difference,0,binary,9,66,11,75,,,,,,,-0.0848389,0.23518906,-0.0728373,0.17353535,,FALSE,TRUE,FALSE,TRUE,"6,563",TEST,HY
468,4802,5515881,memory score,demanding balance training program,relaxation group,significantly increased,1,continuous,,,,,9.44,5.48,8,4.16,cannot calculate,cannot calculate,,,,,Group sizes are in methods section only. Numerical values are from posttest.,TRUE,TRUE,FALSE,FALSE,"4,475",TEST,HY
469,4799,5515881,dynamic balance performance on the stability platform,demanding balance training program,relaxation group,significantly increased,1,continuous,,,,,7.54,2.57,6.29,1.84,cannot calculate,cannot calculate,,,,,Group sizes are in methods section only. Numerical values are from posttest.,TRUE,TRUE,FALSE,FALSE,"4,475",TEST,HY
470,4800,5515881,center of pressure (CoP) sway velocity,demanding balance training program,relaxation group,no significant difference,0,continuous,,,,,0.63,0.11,0.67,0.18,cannot calculate,cannot calculate,,,,,Group sizes are in methods section only. Numerical values are from posttest.,TRUE,TRUE,FALSE,FALSE,"4,475",TEST,HY
471,4803,5515881,spatial score,demanding balance training program,relaxation group,significantly increased,1,continuous,,,,,0.443,0.75,0.04,0.91,cannot calculate,cannot calculate,,,,,Group sizes are in methods section only. Numerical values are from posttest.,TRUE,TRUE,FALSE,FALSE,"4,475",TEST,HY
472,5710,3343759,improvment in ANELT by day 21,higher level of education (>12 years),<12 years of education,significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Median is reported. Group sizes are only available in methods section.,FALSE,TRUE,FALSE,FALSE,"3,838",TEST,HY
473,5711,3343759,aphasia types,very early speech and language therapy (SLT),control,no significant difference,0,binary,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Numerical data is in figure and group sizes are not available in abstract or results sections.,TRUE,FALSE,FALSE,FALSE,"3,838",TEST,HY
474,5522,4144850,Independent household latrines number,Total Sanitation Campaign,Control,significantly increased,1,binary,673,"1,525",366,"1,514",,,,,,,0.90730205,0.00626291,0.60187274,0.00290188,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,"24,614",TEST,HY
475,5523,4144850,Open defecation - adult men,Total Sanitation Campaign,Control,significantly decreased,-1,binary,1138,"1,525",1273,"1,514",,,,,,,-0.5857317,0.00839764,-0.1193432,0.00034804,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,"24,614",TEST,HY
476,5523,4144850,Open defecation - adult women,Total Sanitation Campaign,Control,significantly decreased,-1,binary,1116,"1,525",1264,"1,514",,,,,,,-0.6167847,0.00813218,-0.1317697,0.00037096,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,"24,614",TEST,HY
477,5523,4144850,Open defecation - children,Total Sanitation Campaign,Control,significantly decreased,-1,binary,1279,"1,525",1350,"1,514",,,,,,,-0.4594912,0.0116852,-0.0612653,0.00020636,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,"24,614",TEST,HY
478,5525,4144850,Helminth infections,Total Sanitation Campaign,Control,no significant difference,0,binary,34,581,32,569,,,,,,,0.04217391,0.06435212,0.0397543,0.05718313,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,"24,614",TEST,HY
479,5526,4144850,Anemia,Total Sanitation Campaign,Control,no significant difference,0,binary,"1,078","1,919",976,"1,922",,,,,,,0.21705107,0.00419838,0.10096226,0.00091084,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,"24,614",TEST,HY
480,4801,5515881,VO2peak,demanding balance training program,relaxation group,no significant difference,0,continuous,,,,,32.07,6.52,31.947,7.89,cannot calculate,cannot calculate,,,,,Group sizes are in methods section only. Numerical values are from posttest.,TRUE,TRUE,FALSE,FALSE,"4,475",TEST,HY
481,5521,4144850,Sanitation facility improvement,Total Sanitation Campaign,Control,significantly increased,1,binary,630,"1,522",342,"1,512",,,,,,,0.88220198,0.00648706,0.6043171,0.00319287,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,"24,614",TEST,HY
482,5524,4144850,E. coli contaminated water,Total Sanitation Campaign,Control,no significant difference,0,binary,310,404,331,403,,,,,,,-0.3321747,0.03077414,-0.0680244,0.00129032,Used percent to calculate outcomes for binary variables.,FALSE,TRUE,FALSE,TRUE,"24,614",TEST,HY
483,5712,3343759,Amsterdam-Nijmegen everyday language test (ANELT),very early speech and language therapy (SLT),control,no significant difference,0,continuous,,59,,55,,,,,cannot calculate,cannot calculate,,,,,"Median values are reported. Group size is based on ANELT by day 21, intent-to-treat.",FALSE,TRUE,FALSE,FALSE,"3,838",TEST,HY
484,5713,3343759,history of myocardial infarction,very early speech and language therapy (SLT),control,significantly increased,1,binary,,,,,,,,,,,cannot calculate,cannot calculate,cannot calculate,cannot calculate,Numerical data are only in methods section.,FALSE,TRUE,FALSE,FALSE,"3,838",TEST,HY
485,5714,3343759,communication ability,very early speech and language therapy (SLT),control,no significant difference,0,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Unclear outcome.,FALSE,FALSE,FALSE,FALSE,"3,838",TEST,HY
486,6382,3786549,Improvement in Vaginal Maturation Index,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,significantly increased,1,continuous,,44,,44,35.2,21.7,9.9,14.5,1.35893992,0.05594726,,,,,Numerical values based on intention-to-treat,FALSE,TRUE,FALSE,TRUE,"9,725",TEST,HY
487,6383,3786549,Baseline characteristics: menopause,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,no significant difference,0,continuous,,44,,44,13.11,7.02,13,6.94,0.01562115,0.04545593,,,,,,FALSE,TRUE,FALSE,TRUE,"9,725",TEST,HY
488,6383,3786549,Baseline characteristics: height,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,no significant difference,0,continuous,,44,,44,154.86,5.45,153.43,5.88,0.25003828,0.04580977,,,,,,FALSE,TRUE,FALSE,TRUE,"9,725",TEST,HY
489,6383,3786549,Baseline characteristics: weight,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,no significant difference,0,continuous,,44,,44,56.16,8.1,57.82,8.24,-0.201397,0.045685,,,,,,FALSE,TRUE,FALSE,TRUE,"9,725",TEST,HY
490,6383,3786549,Baseline characteristics: deliveries,Vaginal estriol plus viable Lactobacillus acidophilus KS400,Placebo,no significant difference,0,continuous,,44,,44,2.14,1.76,2.64,1.79,-0.2792152,0.04589751,,,,,,FALSE,TRUE,FALSE,TRUE,"9,725",TEST,HY
491,6484,5419060,Sample rejection rate: CHC A,Phlebotomy training programme,Control,no significant difference,0,binary,79,10218,60,7557,,,,,,,-0.0267831,0.02955691,-0.0265733,0.0290947,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
492,6484,5419060,Sample rejection rate: CHC B,Phlebotomy training programme,Control,no significant difference,0,binary,48,4114,45,3973,,,,,,,0.0300092,0.04355608,0.02966421,0.04256078,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
493,6484,5419060,Sample rejection rate: CDC C,Phlebotomy training programme,Control,no significant difference,0,binary,37,2279,38,2321,,,,,,,-0.0085462,0.05422687,-0.0084069,0.05247318,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
494,6484,5419060,Sample rejection rate: CDC D,Phlebotomy training programme,Control,no significant difference,0,binary,7,630,8,589,,,,,,,-0.2033272,0.27118345,-0.200825,0.26457205,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
495,6488,5419060,Request-form errors: CHC A,Phlebotomy training programme,Control,no significant difference,0,binary,8,10218,11,7557,,,,,,,-0.6208037,0.21613955,-0.6201303,0.2156789,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
496,6488,5419060,Request-form errors: CHC B,Phlebotomy training programme,Control,no significant difference,0,binary,12,4114,11,3973,,,,,,,0.05228567,0.17473861,0.05213706,0.17374765,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
497,6488,5419060,Request-form errors: CDC C,Phlebotomy training programme,Control,no significant difference,0,binary,6,2279,3,2321,,,,,,,0.71275138,0.50087135,0.71140856,0.49913036,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
498,6488,5419060,Request-form errors: CDC D,Phlebotomy training programme,Control,no significant difference,0,binary,0,630,0,589,,,,,,,-0.0672384,4.0032824,-0.0671833,3.9967203,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
499,6489,5419060,Preanalytical errors: CHC A,Phlebotomy training programme,Control,no significant difference,0,binary,27,10218,17,7557,,,,,,,0.16134073,0.09609132,0.16094694,0.09563037,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
500,6489,5419060,Preanalytical errors: CHC B,Phlebotomy training programme,Control,no significant difference,0,binary,12,4114,10,3973,,,,,,,0.14784821,0.18382945,0.14744724,0.18283856,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
501,6489,5419060,Preanalytical errors: CDC C,Phlebotomy training programme,Control,no significant difference,0,binary,10,2279,15,2321,,,,,,,-0.3892899,0.16754104,-0.3872037,0.16579703,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
502,6489,5419060,Preanalytical errors: CDC D,Phlebotomy training programme,Control,no significant difference,0,binary,2,630,4,589,,,,,,,-0.7640755,0.75330176,-0.7604408,0.74671491,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
503,6485,5419060,Phlebotomy questionnaire score: CHC A,Phlebotomy training programme,Control,significantly increased,1,continuous,,23,,23,96,3.89,63,12.31,3.55292234,0.22416584,,,,,Back calculated SD using CI,FALSE,FALSE,FALSE,TRUE,"9,292",TEST,HY
504,6485,5419060,Phlebotomy questionnaire score: CHC B,Phlebotomy training programme,Control,significantly increased,1,continuous,,23,,23,93,1.37,58,7.12,6.70952589,0.57627976,,,,,Back calculated SD using CI,FALSE,FALSE,FALSE,TRUE,"9,292",TEST,HY
505,6485,5419060,Phlebotomy questionnaire score: CDC C,Phlebotomy training programme,Control,significantly increased,1,continuous,,23,,23,97,3.85,60,5.25,7.89939403,0.76522202,,,,,Back calculated SD using CI,FALSE,FALSE,FALSE,TRUE,"9,292",TEST,HY
506,6485,5419060,Phlebotomy questionnaire score: CDC D,Phlebotomy training programme,Control,significantly increased,1,continuous,,23,,23,97,1.21,63,4.31,10.5566479,1.29829148,,,,,Back calculated SD using CI,FALSE,FALSE,FALSE,TRUE,"9,292",TEST,HY
507,6486,5419060,Techinque related rejections: CHC A,Phlebotomy training programme,Control,no significant difference,0,binary,20,10218,20,7557,,,,,,,-0.3023674,0.10023074,-0.3016766,0.09976981,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
508,6486,5419060,Techinque related rejections: CHC B,Phlebotomy training programme,Control,no significant difference,0,binary,15,4114,8,3973,,,,,,,0.59537147,0.19216284,0.59373435,0.1911719,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
509,6486,5419060,Techinque related rejections: CDC C,Phlebotomy training programme,Control,no significant difference,0,binary,18,2279,15,2321,,,,,,,0.20202879,0.12309816,0.20058293,0.12135258,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
510,6486,5419060,Techinque related rejections: CDC D,Phlebotomy training programme,Control,no significant difference,0,binary,2,630,4,589,,,,,,,-0.7640755,0.75330176,-0.7604408,0.74671491,,FALSE,TRUE,FALSE,TRUE,"9,292",TEST,HY
511,6550,4033571,Overall seizure median percent improvement,Extended-release oxcarbazepine 2400 mg,Control,significantly increased,1,continuous,,111,,117,-42.9,,-28.7,,cannot calculate,cannot calculate,,,,,SD was not given,FALSE,FALSE,FALSE,FALSE,"8,206",TEST,HY
512,6553,4033571,Adverse effects,Extended-release oxcarbazepine 1200 mg,Control,no significant difference,0,binary,69,123,67,121,,,,,,,0.02941389,0.06645516,0.01302008,0.01302358,,FALSE,TRUE,FALSE,TRUE,"8,206",TEST,HY
513,6549,4033571,Overall seizure median percent reduction,Extended-release oxcarbazepine 1200 mg,Control,no significant difference,0,continuous,,109,,117,-38.3,,-28.7,,cannot calculate,cannot calculate,,,,,SD was not given,FALSE,FALSE,FALSE,FALSE,"8,206",TEST,HY
514,6551,4033571,Seizure median percent improvement in North America,Extended-release oxcarbazepine 1200 mg,Control,significantly increased,1,continuous,,,,,-34.5,,-13.3,,cannot calculate,cannot calculate,,,,,"Group sizes are only in figure, and SD is not available.",TRUE,FALSE,FALSE,FALSE,"8,206",TEST,HY
515,6552,4033571,Seizure median percent improvement in North America,Extended-release oxcarbazepine 2400 mg,Control,significantly increased,1,continuous,,,,,-52.7,,-13.3,,cannot calculate,cannot calculate,,,,,"Group sizes are only in figure, and SD is not available.",TRUE,FALSE,FALSE,FALSE,"8,206",TEST,HY
516,6554,4033571,Adverse effects,Extended-release oxcarbazepine 2400 mg,Control,significantly increased,1,binary,85,123,67,121,,,,,,,0.58935652,0.07152439,0.22156483,0.01029553,,FALSE,TRUE,FALSE,TRUE,"8,206",TEST,HY
517,6695,5154016,24 h drainage volume,Stypro hemostatic sponge,Gelatin sponge,significantly decreased,-1,continuous,,30,,30,187.9,82,230.8,75,-0.538859,0.06908641,,,,,,FALSE,TRUE,FALSE,TRUE,"3,046",TEST,HY
518,6699,5154016,Second 24 h drainage volume,Stypro hemostatic sponge,Gelatin sponge,no significant difference,0,continuous,,30,,30,53.7,3.8,63.5,14.2,-0.9305774,0.07388312,,,,,,FALSE,TRUE,FALSE,TRUE,"3,046",TEST,HY
519,6700,5154016,Second 24 h drainage volume,Collagen hemostatic sponge,Gelatin sponge,no significant difference,0,continuous,,30,,30,63.3,8.9,63.5,14.2,-0.0166581,0.06666898,,,,,,FALSE,TRUE,FALSE,TRUE,"3,046",TEST,HY
520,6696,5154016,24 h drainage volume,Collagen hemostatic sponge,Gelatin sponge,significantly decreased,-1,continuous,,30,,30,185.2,68,230.8,75,-0.6287208,0.06996075,,,,,,FALSE,TRUE,FALSE,TRUE,"3,046",TEST,HY
521,6697,5154016,Total drainage volume,Stypro hemostatic sponge,Gelatin sponge,significantly decreased,-1,continuous,,30,,30,231.5,18.1,318.5,26.7,-3.7647135,0.18477557,,,,,,FALSE,TRUE,FALSE,TRUE,"3,046",TEST,HY
522,6698,5154016,Total drainage volume,Collagen hemostatic sponge,Gelatin sponge,significantly decreased,-1,continuous,,30,,30,248.5,18.8,318.5,26.7,-2.9921679,0.14127557,,,,,,FALSE,TRUE,FALSE,TRUE,"3,046",TEST,HY
523,6741,5325897,First test results,Evaluation with feedback,Evaluation without feedback,significantly increased,1,continuous,,15,,15,10.24,0.77,9.73,0.77,0.64440958,0.1402544,,,,,,FALSE,FALSE,FALSE,TRUE,"4,260",TEST,HY
524,6741,5325897,Second test results,Evaluation with feedback,Evaluation without feedback,significantly increased,1,continuous,,15,,15,17.73,0.46,12.13,0.47,11.7163546,2.42121609,,,,,,FALSE,FALSE,FALSE,TRUE,"4,260",TEST,HY
525,6742,5325897,Final test results,Evaluation with feedback,Evaluation without feedback,no significant difference,0,continuous,,15,,15,18.53,0.22,18.99,0.22,-2.0343126,0.20230713,,,,,,FALSE,FALSE,FALSE,TRUE,"4,260",TEST,HY
526,6916,4411165,tympanic temperature from Pre to P20 (-0.28 ±0.11°C),"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",significantly decreased,-1,continuous,,10,,10,-0.28,0.11,-0.14,0.05,-1.5691765,0.26155787,,,,,Values on mean change are based on what is reported in abstract. ,TRUE,FALSE,FALSE,TRUE,"3,146",TEST,HY
527,6918,4411165,systolic BP,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",no significant difference,0,continuous,,10,,10,,,,,cannot calculate,cannot calculate,,,,,Numerical values are only in the figures.,TRUE,FALSE,FALSE,FALSE,"3,146",TEST,HY
528,6919,4411165,diastolic BP,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",no significant difference,0,continuous,,10,,10,,,,,cannot calculate,cannot calculate,,,,,Numerical values are only in the figures.,TRUE,FALSE,FALSE,FALSE,"3,146",TEST,HY
529,6915,4411165,effects of cryostimulation on the ANS - heart rate,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",no significant difference,0,continuous,,10,,10,-7.7,2.3,-5.02,1.07,-1.430817,0.25118093,,,,,"Changed from original outcome but adding ""- heart rate"" to make it more specific. Numbers are mean change.",TRUE,FALSE,FALSE,TRUE,"3,146",TEST,HY
530,6917,4411165,Tskin of the head,"whole-body to cold (whole-body cryostimulation, WBC)","whole-body except the head (partial-body cryostimulation, PBC)",no significant difference,0,continuous,,10,,10,,,,,cannot calculate,cannot calculate,,,,,Numerical values are only in the figures.,TRUE,FALSE,FALSE,FALSE,"3,146",TEST,HY
531,7830,4230312,improvement of disorder,quetiapine 600 mg/day,placebo,significantly increased,1,continuous,,289,,204,-14.88,10.54,-11.61,10.12,-0.3148988,0.00846274,,,,,Back calculated SD from SE.,TRUE,FALSE,FALSE,TRUE,"6,201",TEST,HY
532,7829,4230312,improvement of disorder,quetiapine 300 mg/day,placebo,significantly increased,1,continuous,,283,,204,-15.58,10.43,-11.61,10.12,-0.3847888,0.00858754,,,,,Back calculated SD from SE.,TRUE,FALSE,FALSE,TRUE,"6,201",TEST,HY
533,8166,5800236,Months of sick leave,Nacadia® nature-based therapy,Cognitive behavioral therapy,no significant difference,0,continuous,,37,,35,,,,,cannot calculate,cannot calculate,,,,,Numerical values were not given for this outcome.,TRUE,FALSE,FALSE,FALSE,"4,517",TEST,HY
534,7794,3508963,Pain relief,Intravenous lidocaine,Intravenous morphine,significantly increased,1,continuous,,120,,120,1.13,1.15,2.23,1.57,-0.7968282,0.01798945,,,,,Values from 30 minutes.,FALSE,TRUE,FALSE,TRUE,"3,561",TEST,HY
535,7793,3508963,Response to treatment,Intravenous lidocaine,Intravenous morphine,significantly increased,1,binary,108,120,84,120,,,,,,,1.34992672,0.13227513,0.25131443,0.00449735,,FALSE,FALSE,FALSE,TRUE,"3,561",TEST,HY
536,7795,3508963,Baseline characteristics - age,Intravenous lidocaine,Intravenous morphine,no significant difference,0,continuous,,120,,120,35.23,12.37,37.71,11.08,-0.2105282,0.016759,,,,,,FALSE,TRUE,FALSE,TRUE,"3,561",TEST,HY
537,7795,3508963,Baseline characteristics - hydronephrosis in left kidney,Intravenous lidocaine,Intravenous morphine,no significant difference,0,binary,52,120,52,120,,,,,,,0,0.0678733,0,0.02179487,,FALSE,TRUE,FALSE,TRUE,"3,561",TEST,HY
538,7795,3508963,Baseline characteristics - hydronephrosis in right kidney,Intravenous lidocaine,Intravenous morphine,no significant difference,0,binary,57,120,53,120,,,,,,,0.13431725,0.06721017,0.07275935,0.01974512,,FALSE,TRUE,FALSE,TRUE,"3,561",TEST,HY
539,7795,3508963,Baseline characteristics - did not have hydronephrosis,Intravenous lidocaine,Intravenous morphine,no significant difference,0,binary,11,120,15,120,,,,,,,-0.3475425,0.17627388,-0.3101549,0.14090909,,FALSE,TRUE,FALSE,TRUE,"3,561",TEST,HY
540,7795,3508963,Baseline characteristics - history of reurrent stone,Intravenous lidocaine,Intravenous morphine,no significant difference,0,binary,49,120,64,120,,,,,,,-0.504391,0.06797481,-0.2670628,0.0193665,,FALSE,TRUE,FALSE,TRUE,"3,561",TEST,HY
541,7795,3508963,Baseline characteristics - history of first stone,Intravenous lidocaine,Intravenous morphine,no significant difference,0,binary,70,120,56,120,,,,,,,0.47000363,0.06776786,0.22314355,0.01547619,,FALSE,TRUE,FALSE,TRUE,"3,561",TEST,HY
542,7795,3508963,Baseline characteristics - right kidney stone,Intravenous lidocaine,Intravenous morphine,no significant difference,0,binary,60,120,57,120,,,,,,,0.10008346,0.06675021,0.05129329,0.01754386,,FALSE,TRUE,FALSE,TRUE,"3,561",TEST,HY
543,7795,3508963,Baseline characteristics - left kidney stone,Intravenous lidocaine,Intravenous morphine,no significant difference,0,binary,60,120,63,120,,,,,,,-0.1000835,0.06675021,-0.0487902,0.01587302,,FALSE,TRUE,FALSE,TRUE,"3,561",TEST,HY
544,7792,3508963,Pain score after 5 minutes,Intravenous lidocaine,Intravenous morphine,significantly increased,1,continuous,,120,,120,3.18,2.27,4.45,2.16,-0.5713783,0.01734682,,,,,,FALSE,TRUE,FALSE,TRUE,"3,561",TEST,HY
545,8460,3263860,HbA1c reduction,Real-Time Continuous Glucose Monitoring,Control,no significant difference,0,continuous,,69,,68,-0.1,0.6,-0.1,0.6,0,0.02919864,,,,,Mean change,FALSE,TRUE,TRUE,TRUE,"3,178",TEST,HY
546,8461,3263860,Severe hypoglycemia,Real-Time Continuous Glucose Monitoring,Control,no significant difference,0,binary,3,73,5,71,,,,,,,-0.5696661,0.56277056,-0.5386052,0.5055502,,FALSE,TRUE,TRUE,TRUE,"3,178",TEST,HY
547,8463,3263860,Serious skin reactions,Real-Time Continuous Glucose Monitoring,Control,no significant difference,0,binary,0,69,0,68,,,,,,,-0.014493,4.02898703,-0.0143887,3.97122153,Unclear group sizes. Used the group size for 26-week visit.,FALSE,FALSE,TRUE,TRUE,"3,178",TEST,HY
548,8462,3263860,Diabetic ketoacidosis,Real-Time Continuous Glucose Monitoring,Control,no significant difference,0,binary,0,69,0,68,,,,,,,-0.014493,4.02898703,-0.0143887,3.97122153,Unclear group sizes. Used the group size for 26-week visit.,FALSE,FALSE,TRUE,TRUE,"3,178",TEST,HY
549,8464,3263860,PAID questionnaire fear of hypoglycemia,Real-Time Continuous Glucose Monitoring,Control,no significant difference,0,continuous,,69,,68,,,,,cannot calculate,cannot calculate,,,,,Numerical values in Table which is a graphic,FALSE,TRUE,TRUE,FALSE,"3,178",TEST,HY
550,9719,3648394,LF:HF component of HRV,10-week yoga program,Control,significantly increased,1,continuous,,18,,19,0.35,0.43,0.04,0.38,0.74878609,0.1157639,,,,,Numerical values are from Week 11.,FALSE,TRUE,FALSE,TRUE,"9,556",TEST,HY
551,9724,3648394,Push-up test,10-week yoga program,Control,no significant difference,0,continuous,,18,,19,21,11,20,13,0.08105953,0.10827593,,,,,Numerical values are from Week 11.,FALSE,TRUE,FALSE,TRUE,"9,556",TEST,HY
552,9725,3648394,Quality of life - PCS (SF36),10-week yoga program,Control,no significant difference,0,continuous,,18,,19,47.5,2.7,46.9,4.8,0.1496389,0.10848973,,,,,"Original outcome was just ""Quality of Life"". Numerical values are from Week 11.",FALSE,TRUE,FALSE,TRUE,"9,556",TEST,HY
553,9725,3648394,Quality of life - MCS (SF36),10-week yoga program,Control,no significant difference,0,continuous,,18,,19,47.5,10.6,48.5,7.7,-0.1060797,0.1083392,,,,,"Original outcome was just ""Quality of Life"". Numerical values are from Week 11.",FALSE,TRUE,FALSE,TRUE,"9,556",TEST,HY
554,9720,3648394,pNN50,10-week yoga program,Control,significantly decreased,-1,continuous,,18,,19,20.7,25.3,19.4,18.4,0.05775336,0.10823221,,,,,Numerical values are from Week 11.,FALSE,TRUE,FALSE,TRUE,"9,556",TEST,HY
555,9721,3648394,Flexibility,10-week yoga program,Control,significantly increased,1,continuous,,18,,19,31,8.7,26.4,10.4,0.46823146,0.11114985,,,,,Numerical values are from Week 11 data for sit and reach test.,FALSE,TRUE,FALSE,TRUE,"9,556",TEST,HY
556,9828,3136370,Fibromyalgia Impact Questionnaire scores,Soy shake,Control,significantly decreased,-1,continuous,,12,,16,-17.1,68.08,-19.57,93.53,0.02864501,0.14584799,,,,,From per protocol,FALSE,TRUE,FALSE,TRUE,"6,022",TEST,HY
557,9830,3136370,Fibromyalgia Impact Questionnaire scores,Soy shake,Casein shake (Placebo),no significant difference,0,continuous,,12,,16,-17.1,68.08,-19.57,93.53,0.02864501,0.14584799,,,,,From per protocol,FALSE,TRUE,FALSE,TRUE,"6,022",TEST,HY
558,9831,3136370,Center for Epidemiologic Studies Depression Scale score,Soy shake,Control,no significant difference,0,continuous,,12,,16,-4,12.35,-8,65.41,0.07716042,0.14593965,,,,,From per protocol,FALSE,TRUE,FALSE,TRUE,"6,022",TEST,HY
559,9833,3136370,Center for Epidemiologic Studies Depression Scale score,Soy shake,Casein shake (Placebo),no significant difference,0,continuous,,12,,16,-4,12.35,-8,65.41,0.07716042,0.14593965,,,,,From per protocol,FALSE,TRUE,FALSE,TRUE,"6,022",TEST,HY
560,9834,3496170,Learned irrelevance index,Biperiden,Placebo,no significant difference,0,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Group sizes are not available and numerical data in figure.,TRUE,FALSE,TRUE,FALSE,"2,318",TEST,HY
561,9835,3496170,P3a amplitude,Biperiden,Placebo,no significant difference,0,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Group sizes are not available and numerical data in figure.,TRUE,FALSE,TRUE,FALSE,"2,318",TEST,HY
562,9836,3496170,P3a latency,Biperiden,Placebo,no significant difference,0,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Group sizes are not available and numerical data in figure.,TRUE,FALSE,TRUE,FALSE,"2,318",TEST,HY
563,9837,3496170,Self-report questionnaire,Biperiden,Placebo,no significant difference,0,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,No numerical values are given.,FALSE,FALSE,TRUE,FALSE,"2,318",TEST,HY
564,9838,3496170,N1 latency,Biperiden,Placebo,no significant difference,0,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Group sizes are not available and numerical data in figure.,TRUE,FALSE,TRUE,FALSE,"2,318",TEST,HY
565,9839,3496170,N1 amplitude,Biperiden,Placebo,significantly increased,1,continuous,,,,,,,,,cannot calculate,cannot calculate,,,,,Group sizes are not available and numerical data is not given.,FALSE,FALSE,TRUE,FALSE,"2,318",TEST,HY
566,8556,5541727,Knee Injury and Osteoarthritis Outcome Score improvement,Allogeneic mesenchymal precursor cells,Control,significantly increased,1,continuous,,11,,6,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,"6,118",TEST,HY
567,8560,5541727,Tibial bone expansion,Allogeneic mesenchymal precursor cells,Control,significantly decreased,-1,continuous,,11,,6,-0.7,1.5,1,1.1,-1.1693949,0.29779588,,,,,"Values are from ""total tibial plateau"" for 24 months",FALSE,TRUE,FALSE,TRUE,"6,118",TEST,HY
568,8555,5541727,Treatment-related serious adverse events,Allogeneic mesenchymal precursor cells,Control,no significant difference,0,binary,0,11,0,6,,,,,,,-0.5705449,4.24080268,-0.5389965,3.77380952,,FALSE,FALSE,FALSE,TRUE,"6,118",TEST,HY
569,8557,5541727,Activities of daily living,Allogeneic mesenchymal precursor cells,Control,significantly increased,1,continuous,,11,,6,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,"6,118",TEST,HY
570,8558,5541727,Symptom improvement,Allogeneic mesenchymal precursor cells,Control,significantly increased,1,continuous,,11,,6,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,"6,118",TEST,HY
571,8559,5541727,SF-36 bodily pain score improvement,Allogeneic mesenchymal precursor cells,Control,significantly increased,1,continuous,,11,,6,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,"6,118",TEST,HY
572,8561,5541727,medial tibial cartilage volume loss,Allogeneic mesenchymal precursor cells,Control,no significant difference,0,continuous,,11,,6,-1.4,4.2,-3.3,5.3,0.39232146,0.2621027,,,,,Values are from 24 months,FALSE,TRUE,FALSE,TRUE,"6,118",TEST,HY
573,8561,5541727,lateral tibial cartilage volume loss,Allogeneic mesenchymal precursor cells,Control,no significant difference,0,continuous,,11,,6,-3.7,3.4,-0.8,3.5,-0.8015134,0.27647057,,,,,Values are from 24 months,FALSE,TRUE,FALSE,TRUE,"6,118",TEST,HY
574,8565,2952311,Verbal rating scale pain intensity,Acupressure at distal points,Control,significantly decreased,-1,continuous,,11,,11,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,"3,603",TEST,HY
575,8562,2952311,Verbal rating scale pain intensity,Acupressure at local points,Control,significantly decreased,-1,continuous,,11,,11,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,"3,603",TEST,HY
576,8563,2952311,State-Trait Anxiety Inventory-I,Acupressure at local points,Control,significantly decreased,-1,continuous,,11,,11,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,"3,603",TEST,HY
577,8567,2952311,Salivary alpha-amylase,Acupressure at distal points,Acupressure at local points,no significant difference,0,continuous,,11,,11,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,"3,603",TEST,HY
578,8564,2952311,Muscle hardness,Acupressure at local points,Control,significantly decreased,-1,continuous,,11,,11,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,"3,603",TEST,HY
579,8566,2952311,State-Trait Anxiety Inventory-I,Acupressure at distal points,Control,significantly decreased,-1,continuous,,11,,11,,,,,cannot calculate,cannot calculate,,,,,Numerical values in figure.,TRUE,FALSE,FALSE,FALSE,"3,603",TEST,HY
580,10217,3504298,Anxious symptoms,Face-based attentional bias modification,Placebo,significantly decreased,-1,continuous,,16,,14,,,,,cannot calculate,cannot calculate,,,,,"F-values given, cant use for point estimates, and values in figure",TRUE,FALSE,FALSE,FALSE,"4,963",TEST,DP
581,11584,115849,Discontinuation due to lack of efficacy,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,no significant difference,0,continuous,,353,,181,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
582,10219,3504298,Attentional Function,Word-based attentional bias modification,Face-based attentional bias modification,no significant difference,0,continuous,,16,,16,,,,,cannot calculate,cannot calculate,,,,,"F-values given, cant use for point estimates, and values in figure",TRUE,FALSE,FALSE,FALSE,"4,963",TEST,DP
583,10218,3504298,Difference of cortisol on waking and the highest level of following samples,Word-based attentional bias modification,Placebo,no significant difference,0,continuous,,16,,15,,,,,cannot calculate,cannot calculate,,,,,"F-values given, cant use for point estimates, and values in figure",TRUE,FALSE,FALSE,FALSE,"4,963",TEST,DP
584,10215,3504298,Depressive symptoms,Face-based attentional bias modification,Placebo,significantly decreased,-1,continuous,,16,,14,,,,,cannot calculate,cannot calculate,,,,,"F-values given, cant use for point estimates",FALSE,FALSE,FALSE,FALSE,"4,963",TEST,DP
585,10216,3504298,Depressive symptoms,Word-based attentional bias modification,Placebo,no significant difference,0,continuous,,16,,15,,,,,cannot calculate,cannot calculate,,,,,"F-values given, cant use for point estimates",FALSE,FALSE,FALSE,FALSE,"4,963",TEST,DP
586,11522,547916,matrix metalloproteinase-9 (MMP-9),doxycycline (100 mg),placebo,significantly decreased,-1,continuous,,10,,4,2.18,1.94,3.26,3.58,-0.4117458,0.35605481,,,,,found in abstract,FALSE,FALSE,FALSE,TRUE,"4,542",TEST,DP
587,11581,115849,patients discontinued due to lack of efficacy,etoricoxib 90 mg once daily,placebo,significantly decreased,-1,binary,44,353,90,357,,,,,,,-0.8617127,0.04081995,-0.7043523,0.0282044,found in fig 1,TRUE,FALSE,FALSE,TRUE,"6,464",TEST,DP
588,11581,115849,patients discontinued due to lack of efficacy,naproxen 500 mg twice daily,placebo,significantly decreased,-1,binary,19,181,90,357,,,,,,,-1.0557184,0.07366085,-0.8761319,0.05541671,found in fig 1,TRUE,FALSE,FALSE,TRUE,"6,464",TEST,DP
589,11583,115849,Patient global assessment of disease activity,etoricoxib 90 mg once daily,placebo,significantly increased,1,continuous,,353,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
590,11583,115849,investigator global assessment of disease activity,etoricoxib 90 mg once daily,placebo,significantly increased,1,continuous,,353,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
591,11583,115849,Tender joint count,etoricoxib 90 mg once daily,placebo,significantly increased,1,continuous,,353,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
592,11583,115849,Swollen joint count,etoricoxib 90 mg once daily,placebo,significantly increased,1,continuous,,353,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
593,11583,115849,Patient global assessment of pain,etoricoxib 90 mg once daily,placebo,significantly increased,1,continuous,,353,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
594,11583,115849,Health Assessment Questionnaire disability,etoricoxib 90 mg once daily,placebo,significantly increased,1,continuous,,353,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
595,11583,115849,Serum C-reactive protein,etoricoxib 90 mg once daily,placebo,significantly increased,1,continuous,,353,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
596,11583,115849,ACR20 responder criteria,etoricoxib 90 mg once daily,placebo,significantly increased,1,continuous,,353,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
597,11583,115849,Discontinuation due to lack of efficacy,etoricoxib 90 mg once daily,placebo,significantly increased,1,continuous,,353,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
598,11583,115849,Patient global assessment of disease activity,naproxen 500 mg twice daily,placebo,significantly increased,1,continuous,,181,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
599,11583,115849,investigator global assessment of disease activity,naproxen 500 mg twice daily,placebo,significantly increased,1,continuous,,181,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
600,11583,115849,Tender joint count,naproxen 500 mg twice daily,placebo,significantly increased,1,continuous,,181,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
601,11583,115849,Swollen joint count,naproxen 500 mg twice daily,placebo,significantly increased,1,continuous,,181,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
602,11583,115849,Patient global assessment of pain,naproxen 500 mg twice daily,placebo,significantly increased,1,continuous,,181,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
603,11583,115849,Health Assessment Questionnaire disability,naproxen 500 mg twice daily,placebo,significantly increased,1,continuous,,181,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
604,11583,115849,Serum C-reactive protein,naproxen 500 mg twice daily,placebo,significantly increased,1,continuous,,181,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
605,11583,115849,ACR20 responder criteria,naproxen 500 mg twice daily,placebo,significantly increased,1,continuous,,181,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
606,11583,115849,Discontinuation due to lack of efficacy,naproxen 500 mg twice daily,placebo,significantly increased,1,continuous,,181,,357,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
607,11584,115849,Patient global assessment of disease activity,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,no significant difference,0,continuous,,353,,181,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
608,11584,115849,investigator global assessment of disease activity,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,no significant difference,0,continuous,,353,,181,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
609,11584,115849,Tender joint count,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,no significant difference,0,continuous,,353,,181,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
610,11584,115849,Swollen joint count,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,no significant difference,0,continuous,,353,,181,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
611,11584,115849,Patient global assessment of pain,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,no significant difference,0,continuous,,353,,181,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
612,11584,115849,Health Assessment Questionnaire disability,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,no significant difference,0,continuous,,353,,181,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
613,11584,115849,Serum C-reactive protein,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,no significant difference,0,continuous,,353,,181,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
614,11584,115849,ACR20 responder criteria,etoricoxib 90 mg once daily,naproxen 500 mg twice daily,no significant difference,0,continuous,,353,,181,,,,,cannot calculate,cannot calculate,,,,,"found in table 2, but differences given rather than raw values. Also ranges provided rather than STD, cannot calculate",FALSE,TRUE,FALSE,FALSE,"6,464",TEST,DP
615,11602,1863515,haemoglobin level between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,significantly decreased,-1,continuous,,754,,656,-0.4,,0,,cannot calculate,cannot calculate,,,,,"given as estimated change and no std given, also in figure and graphic format",TRUE,TRUE,TRUE,FALSE,"3,963",TEST,DP
616,11602,1863515,leucocyte count between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,significantly decreased,-1,continuous,,754,,656,-423,,0,,cannot calculate,cannot calculate,,,,,"given as estimated change and no std given, also in figure and graphic format",TRUE,TRUE,TRUE,FALSE,"3,963",TEST,DP
617,11602,1863515,absolute neutrophil count between 26 and 35 wk,Zidovudine prophylaxis initiation,placebo,significantly decreased,-1,continuous,,754,,656,-485,,0,,cannot calculate,cannot calculate,,,,,"given as estimated change and no std given, also in figure and graphic format",TRUE,TRUE,TRUE,FALSE,"3,963",TEST,DP
618,11603,1863515,haemoglobin level at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,significantly increased,1,continuous,,754,,656,10.7,,11.2,,cannot calculate,cannot calculate,,,,,"means given but no std given, tables and figures in graphic format",TRUE,TRUE,TRUE,FALSE,"3,963",TEST,DP
619,11603,1863515,leucocyte count at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,significantly increased,1,continuous,,754,,656,8818,,8362,,cannot calculate,cannot calculate,,,,,"means given but no std given, tables and figures in graphic format",TRUE,TRUE,TRUE,FALSE,"3,963",TEST,DP
620,11603,1863515,absolute neutrophil count at 35 wk gestation,Zidovudine prophylaxis initiation,placebo,significantly increased,1,continuous,,754,,656,5639,,6150,,cannot calculate,cannot calculate,,,,,"means given but no std given, tables and figures in graphic format",TRUE,TRUE,TRUE,FALSE,"3,963",TEST,DP
621,11904,3493722,eradication rate of H. pylori in ITT,1-week quadruple rescue therapy,2-week quadruple rescue therapy,no significant difference,0,binary,71,85,72,84,,,,,,,-0.1681369,0.1827353,-0.0258207,0.00430393,"found in abstract and table, assumed binary because given as percentage of population",FALSE,FALSE,FALSE,TRUE,"1,684",TEST,DP
622,11904,3493722,eradication rate of H. pylori in PP,1-week quadruple rescue therapy,2-week quadruple rescue therapy,no significant difference,0,binary,71,81,72,81,,,,,,,-0.1193468,0.23908451,-0.0139862,0.00328204,"found in abstract and table, assumed binary because given as percentage of population",FALSE,FALSE,FALSE,TRUE,"1,684",TEST,DP
623,11905,3493722,side effects,1-week quadruple rescue therapy,2-week quadruple rescue therapy,no significant difference,0,binary,19,85,32,84,,,,,,,-0.7597079,0.11826386,-0.5331314,0.06021211,found in results section,FALSE,FALSE,FALSE,TRUE,"1,684",TEST,DP
624,11906,3493722,good compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,no significant difference,0,binary,74,81,74,81,,,,,,,0,0.31274131,0,0.00233567,"found in table 2, assumed binary because proportion of whole given",FALSE,TRUE,TRUE,TRUE,"1,684",TEST,DP
625,11906,3493722,well compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,no significant difference,0,binary,8,81,4,81,,,,,,,0.74649316,0.40168564,0.69314718,0.35030864,"found in table 2, assumed binary because proportion of whole given",FALSE,TRUE,TRUE,TRUE,"1,684",TEST,DP
626,11906,3493722,poor compliance rates,1-week quadruple rescue therapy,2-week quadruple rescue therapy,no significant difference,0,binary,2,81,3,81,,,,,,,-0.4182041,0.85881207,-0.4054651,0.80864198,"found in table 2, assumed binary because proportion of whole given",FALSE,TRUE,TRUE,TRUE,"1,684",TEST,DP
627,12232,3510731,Clicked on Results link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,significantly decreased,-1,binary,247,6051,515,5892,,,,,,,-0.8111953,0.0063486,-0.7614066,0.00565535,found in table 1,FALSE,TRUE,FALSE,TRUE,"1,665",TEST,DP
628,12233,3510731,Clicked on Protocol link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,significantly decreased,-1,binary,202,6051,362,5892,,,,,,,-0.6394594,0.00806473,-0.6100046,0.00737794,found in table 1,FALSE,TRUE,FALSE,TRUE,"1,665",TEST,DP
629,12234,3510731,Median time in seconds (interquartile range) - Results link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,no significant difference,0,continuous,,6051,,5892,25,,25.3,,cannot calculate,cannot calculate,,,,,"found in table 1, IQ range given rather and std",FALSE,TRUE,FALSE,FALSE,"1,665",TEST,DP
630,12235,3510731,Median time in seconds (interquartile range) - Protocol link,received the debriefing information in the body of an email with links to protocol and results pages;,received these links after clicking on an initial link in the body of the email to view the debriefing information on a website.,no significant difference,0,continuous,,6051,,5892,3.5,,3.6,,cannot calculate,cannot calculate,,,,,"found in table 1, IQ range given rather and std",FALSE,TRUE,FALSE,FALSE,"1,665",TEST,DP
631,12275,3936115,The number of diverticulitis clinical symptom occurrences during 12months,Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,significantly decreased,-1,binary,2,30,7,22,,,,,,,-1.8769173,0.7452381,-1.5629179,0.56406926,found in table 1,FALSE,TRUE,FALSE,TRUE,"2,217",TEST,DP
632,12276,3936115,the number of abdominal ultrasound examinations performed for suspected diverticulitis and subsequent number of diverticulitis diagnosed based on abdominal US,Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,significantly decreased,-1,binary,1,30,5,22,,,,,,,-2.1435204,1.29330629,-1.9195928,1.12121212,found in table 2,FALSE,TRUE,FALSE,TRUE,"2,217",TEST,DP
633,12277,3936115,"Subjective improvement in observed symptoms based on a single closed-end question (yes or no answer): ""Did you observe adequate relief of diverticulosis related to abdominal pain or discomfort within the past 12 months?""",Microencapsulated sodium butyrate (MSB) 300 mg daily,control group was administered placebo,significantly increased,1,binary,17,30,5,22,,,,,,,1.49203942,0.39457014,0.9136205,0.18003565,found in table 3,FALSE,TRUE,FALSE,TRUE,"2,217",TEST,DP
634,12289,5777645,HbA1c levels,to peer-led structured patient education,conventional care alone,significantly decreased,-1,continuous,,70,,70,1.05,2,0.15,1.7,0.48225433,0.02940203,,,,,SDs found in abstract while group sizes and means found in table 2,FALSE,TRUE,FALSE,TRUE,"8,661",TEST,DP
635,12290,5777645,Mean BMI change,to peer-led structured patient education,conventional care alone,significantly decreased,-1,continuous,,,,,-1.65,2.5,0.05,3.2,,,,,,,SDs found in abstract while group sizes and means found in table 2,FALSE,TRUE,FALSE,TRUE,"8,661",TEST,DP
636,12291,5777645,Mean waist circumference,to peer-led structured patient education,conventional care alone,significantly decreased,-1,continuous,,,,,-3.34,9.3,2.65,10.3,,,,,,,SDs found in abstract while group sizes and means found in table 2,FALSE,TRUE,FALSE,TRUE,"8,661",TEST,DP
637,12720,4132222,decrease in average lesion,application of a canola phenolic acid-based cream (CPA),placebo,,,continuous,,30,,15,,,,,cannot calculate,cannot calculate,,,,,no raw values given and can only be estimated from figure,FALSE,FALSE,FALSE,FALSE,"2,177",TEST,DP
638,12721,4132222,"higher prevalence of lesion scabbing, a sign of healing",application of a canola phenolic acid-based cream (CPA),placebo,no significant difference,0,continuous,,30,,15,,,,,cannot calculate,cannot calculate,,,,,no raw values given and can only be estimated from figure,FALSE,FALSE,FALSE,FALSE,"2,177",TEST,DP
639,12772,4511433,LDL cholesterol,5 mg elobixibat,placebo,significantly decreased,-1,continuous,,12,,12,,,,,cannot calculate,cannot calculate,,,,,no raw values given and can only be estimated from figure,FALSE,FALSE,FALSE,FALSE,"4,648",TEST,DP
640,12772,4511433,LDL cholesterol,2.5 mg,placebo,significantly decreased,-1,continuous,,12,,12,,,,,cannot calculate,cannot calculate,,,,,no raw values given and can only be estimated from figure,FALSE,FALSE,FALSE,FALSE,"4,648",TEST,DP
641,12879,5830087,objective response rate (ORR),"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),no significant difference,0,binary,29,48,19,23,,,,,,,-1.1352878,0.38974592,-0.3128499,0.02280274,found in table 2,FALSE,TRUE,FALSE,TRUE,"11,942",TEST,DP
642,12880,5830087,disease control rate,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),no significant difference,0,binary,45,48,21,23,,,,,,,0.35667494,0.9031746,0.02643326,0.00552968,found in table 2,FALSE,TRUE,FALSE,TRUE,"11,942",TEST,DP
643,12880,5830087,duration of objective response,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),no significant difference,0,continuous,,48,,23,,,,,cannot calculate,cannot calculate,,,,,"given as median with confidence interval, cannot calculate",FALSE,TRUE,FALSE,FALSE,"11,942",TEST,DP
644,12880,5830087,progression-free survival,"BTH1677 arm ( intravenous [IV] BTH1677, 4 mg/kg, weekly; IV bevacizumab, 15 mg/kg, once each 3-week cycle [Q3W]; IV carboplatin, 6 mg/mL/min Calvert formula area-under-the-curve, Q3W; and IV paclitaxel, 200 mg/m2, Q3W)",Control arm ( bevacizumab/carboplatin/paclitaxel as above),no significant difference,0,continuous,,48,,23,,,,,cannot calculate,cannot calculate,,,,,"given as median with confidence interval, cannot calculate",FALSE,TRUE,FALSE,FALSE,"11,942",TEST,DP
645,13025,4675066,The mean cognitive score on the Bayley-III,iodine (150 μg/d),placebo,no significant difference,0,continuous,,27,,26,99.4,12.2,101.7,8.2,-0.2172012,0.07594364,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,"6,682",TEST,DP
646,13025,4675066,The mean language score on the Bayley-III,iodine (150 μg/d),placebo,no significant difference,0,continuous,,27,,26,97.2,12.2,97.9,11.5,-0.058139,0.07553046,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,"6,682",TEST,DP
647,13025,4675066,The mean motor score on the Bayley-III,iodine (150 μg/d),placebo,no significant difference,0,continuous,,27,,26,93.9,10.8,92.4,9.7,0.14381908,0.07569371,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,"6,682",TEST,DP
648,13097,5976307,induction time,etomidate,propofol based on midazolam,no significant difference,0,continuous,,62,,62,2.46,0.993,2.21,1,0.24933056,0.03250873,,,,,found in table 2,FALSE,TRUE,TRUE,TRUE,"2,560",TEST,DP
649,13097,5976307,total procedure time,etomidate,propofol based on midazolam,no significant difference,0,continuous,,62,,62,29.73,12.23,29.46,16.04,0.01881372,0.03225949,,,,,found in table 2,FALSE,TRUE,TRUE,TRUE,"2,560",TEST,DP
650,13097,5976307,awake time,etomidate,propofol based on midazolam,no significant difference,0,continuous,,62,,62,15.08,10.06,17.07,11.83,-0.1801099,0.03238887,,,,,found in table 2,FALSE,TRUE,TRUE,TRUE,"2,560",TEST,DP
651,13098,5976307,The incidence rate of all cardiopulmonary adverse events,etomidate,propofol based on midazolam,significantly decreased,-1,binary,34,62,45,62,,,,,,,-0.7792931,0.1461718,-0.280302,0.01937592,found in table 3,FALSE,TRUE,TRUE,TRUE,"2,560",TEST,DP
652,13099,5976307,The incidence rate of vital sign fluctuation (VSF),etomidate,propofol based on midazolam,significantly decreased,-1,binary,17,62,31,62,,,,,,,-0.9734491,0.14556188,-0.6007739,0.05882353,found in table 3,FALSE,TRUE,TRUE,TRUE,"2,560",TEST,DP
653,13100,5976307,the incidence rate of adverse events disturbing the procedure,etomidate,propofol based on midazolam,,,binary,16,62,5,62,,,,,,,1.37756068,0.30178299,1.16315081,0.23024194,found in table 3,FALSE,TRUE,TRUE,TRUE,"2,560",TEST,DP
654,13101,5976307,The incidence rate of myoclonus,etomidate,propofol based on midazolam,significantly increased,1,binary,10,62,1,62,,,,,,,2.46221524,1.13562421,2.30258509,1.06774194,found in table 3,FALSE,TRUE,TRUE,TRUE,"2,560",TEST,DP
655,13175,5773985,mean volume of both the solutions used,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,no significant difference,0,continuous,,25,,25,4.15,0.52,4.12,0.6,0.05259525,0.08002766,,,,,Found in abstract and results,FALSE,FALSE,FALSE,TRUE,"2,609",TEST,DP
656,13176,5773985,subjective onset of action,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,no significant difference,0,continuous,,25,,25,3,1.08,2.92,1.03,0.07461636,0.08005568,,,,,Found in abstract and results,FALSE,FALSE,FALSE,TRUE,"2,609",TEST,DP
657,13176,5773985,objective onset of action,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,no significant difference,0,continuous,,25,,25,7.4,1.93,7.28,1.59,0.06679907,0.08004462,,,,,Found in abstract and results,FALSE,FALSE,FALSE,TRUE,"2,609",TEST,DP
658,13177,5773985,duration of surgical procedure,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,no significant difference,0,continuous,,25,,25,32.2,15.5,33.68,18.91,-0.0842565,0.08007099,,,,,Graphic format table,FALSE,TRUE,TRUE,TRUE,"2,609",TEST,DP
659,13178,5773985,the mean duration of postoperative analgesia,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,significantly decreased,-1,continuous,,25,,25,508.92,63.3,1840.84,819.51,-2.2556182,0.13087813,,,,,Found in abstract and results,FALSE,FALSE,FALSE,TRUE,"2,609",TEST,DP
660,13179,5773985,number of analgesic tablets,0.5% bupivacaine with 1:200000 epinephrine in group I,mixture of 39 ml of 0.5% bupivacaine with epinephrine 1:200000 and 1 ml of 300 _g buprenorphine (3 _g/kg)in group II,significantly increased,1,continuous,,25,,25,1.64,0.99,0.8,1.08,0.7980815,0.08636934,,,,,Graphic format table,FALSE,TRUE,TRUE,TRUE,"2,609",TEST,DP
661,13216,4458006,amplitude of whisking,facial nerve transection and subsequent repair either at the main trunk of the nerve (group 1),"2 cm distally, at the main bifurcation (group 2)",no significant difference,0,continuous,,12,,12,17.2,,6.9,,cannot calculate,cannot calculate,,,,,No std given,FALSE,FALSE,FALSE,FALSE,"1,302",TEST,DP
662,13294,4987981,"Psoriasis Area and Severity Index (PASI), Erythema, Scaling and Induration (ESI) and Physician global assessment (PGA) scores",metformin or pioglitazone,placebo,significantly decreased,-1,continuous,,37,,23,,,,,cannot calculate,cannot calculate,,,,,Values combined and given in figure,TRUE,FALSE,FALSE,FALSE,"9,637",TEST,DP
663,13295,4987981,percentage of patients achieving 75 % reduction in PASI and ESI scores,metformin or pioglitazone,placebo,significantly increased,1,continuous,,37,,23,,,,,cannot calculate,cannot calculate,,,,,Values combined and given in figure,TRUE,FALSE,FALSE,FALSE,"9,637",TEST,DP
664,13296,4987981,FPG,metformin,placebo,no significant difference,0,continuous,,21,,23,101.9,35.1,97.6,20.8,0.14806913,0.09134645,,,,,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,"9,637",TEST,DP
665,13296,4987981,FPG,pioglitazone,placebo,no significant difference,0,continuous,,16,,23,103.4,28.9,97.6,20.8,0.23275367,0.1066728,,,,,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,"9,637",TEST,DP
666,13296,4987981,total cholesterol,metformin,placebo,no significant difference,0,continuous,,21,,23,206.9,36.2,184.4,37.5,0.59900785,0.0951747,,,,,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,"9,637",TEST,DP
667,13296,4987981,total cholesterol,pioglitazone,placebo,no significant difference,0,continuous,,16,,23,207.2,42.3,184.4,37.5,0.5651889,0.11007363,,,,,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,"9,637",TEST,DP
668,13296,4987981,triglycerides levels,metformin,placebo,no significant difference,0,continuous,,21,,23,194.3,63.1,181.8,61.3,0.19746629,0.09154041,,,,,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,"9,637",TEST,DP
669,13296,4987981,triglycerides levels,pioglitazone,placebo,no significant difference,0,continuous,,16,,23,200.1,55.9,181.8,61.3,0.30295813,0.10715497,,,,,Values seperated and found in table,FALSE,TRUE,FALSE,TRUE,"9,637",TEST,DP
670,13297,4987981,IL-6 and TNF-α levels,metformin or pioglitazone,placebo,no significant difference,0,continuous,,37,,23,,,,,cannot calculate,cannot calculate,,,,,Values combined and given in figure,TRUE,FALSE,FALSE,FALSE,"9,637",TEST,DP
671,13313,4550271,Community knowledge,provider,control,no significant difference,0,continuous,,14,,12,,,,,cannot calculate,cannot calculate,,,,,outcome too broad,FALSE,TRUE,FALSE,FALSE,"24,886",TEST,DP
672,13313,4550271,Community knowledge,provider-school intervention,control,no significant difference,0,continuous,,14,,12,,,,,cannot calculate,cannot calculate,,,,,outcome too broad,FALSE,TRUE,FALSE,FALSE,"24,886",TEST,DP
673,13314,4550271,treatment according to guidelines,provider,control,no significant difference,0,continuous,,14,,12,36.4,32,22.6,23,0.47332022,0.15907021,,,,,mean given as percent and std has no unit,FALSE,TRUE,FALSE,TRUE,"24,886",TEST,DP
674,13314,4550271,treatment according to guidelines,provider-school intervention,control,no significant difference,0,continuous,,14,,12,23.5,26,22.6,23,0.035327,0.1547859,,,,,mean given as percent and std has no unit,FALSE,TRUE,FALSE,TRUE,"24,886",TEST,DP
675,13315,4550271,the proportion of patients who tested positive and received (or were prescribed) an ACT,provider,control,no significant difference,0,continuous,,14,,12,56.1,31,64.2,28,-0.2644318,0.1561066,,,,,mean given as percent and std has no unit,FALSE,TRUE,FALSE,TRUE,"24,886",TEST,DP
676,13315,4550271,the proportion of patients who tested positive and received (or were prescribed) an ACT,provider-school intervention,control,no significant difference,0,continuous,,14,,12,56.4,33,64.2,28,-0.2451619,0.15591776,,,,,mean given as percent and std has no unit,FALSE,TRUE,FALSE,TRUE,"24,886",TEST,DP
677,13505,5777419,the total cultivable microbiota,probiotic,placebo,no significant difference,0,continuous,,16,,15,,,,,cannot calculate,cannot calculate,,,,,median and IQ scores given,FALSE,TRUE,FALSE,FALSE,"9,410",TEST,DP
678,13505,5777419,the total cultivable microbiota,antibiotic,placebo,no significant difference,0,continuous,,16,,15,,,,,cannot calculate,cannot calculate,,,,,median and IQ scores given,FALSE,TRUE,FALSE,FALSE,"9,410",TEST,DP
679,13506,5777419,attachment gain,probiotic,placebo,no significant difference,0,continuous,,16,,15,3.4,0.6,4.3,1.4,-0.8236508,0.14010861,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,"9,410",TEST,DP
680,13506,5777419,reduction of PPD,probiotic,placebo,no significant difference,0,continuous,,16,,15,2.2,0.3,2.5,0.6,-0.6224049,0.13541486,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,"9,410",TEST,DP
681,13506,5777419,reduction of plaque,probiotic,placebo,no significant difference,0,continuous,,16,,15,28.1,14.6,27.4,13,0.0492187,0.12920574,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,"9,410",TEST,DP
682,13506,5777419,attachment gain,antibiotic,placebo,no significant difference,0,continuous,,16,,15,4.1,1,4.3,1.4,-0.1610069,0.12958478,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,"9,410",TEST,DP
683,13506,5777419,reduction of PPD,antibiotic,placebo,no significant difference,0,continuous,,16,,15,2.3,0.3,2.5,0.6,-0.4149366,0.13194364,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,"9,410",TEST,DP
684,13506,5777419,reduction of plaque,antibiotic,placebo,no significant difference,0,continuous,,16,,15,31.8,14.8,27.4,13,0.30695109,0.13068633,,,,,found in table 2,FALSE,TRUE,FALSE,TRUE,"9,410",TEST,DP
685,13760,2836833,Fecal fat loss,1500 mg calcium,500 mg calcium,significantly increased,1,continuous,,17,,17,,,,,cannot calculate,cannot calculate,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",FALSE,TRUE,FALSE,FALSE,"12,992",TEST,DP
686,13761,2836833,Urinary calcium excretion,1500 mg calcium,500 mg calcium,significantly increased,1,continuous,,17,,17,,,,,cannot calculate,cannot calculate,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",FALSE,TRUE,FALSE,FALSE,"12,992",TEST,DP
687,13762,2836833,weight loss,1500 mg calcium,500 mg calcium,no significant difference,0,continuous,,17,,17,,,,,cannot calculate,cannot calculate,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",FALSE,TRUE,FALSE,FALSE,"12,992",TEST,DP
688,13763,2836833,systolic or diastolic blood pressure,1500 mg calcium,500 mg calcium,no significant difference,0,continuous,,17,,17,,,,,cannot calculate,cannot calculate,,,,,"assumed group sizes were half and half of 34, values for low and high calcium groups have multiple seperated groups within them",FALSE,TRUE,FALSE,FALSE,"12,992",TEST,DP
689,13830,4210722,vaccination certificates were submitted,a separate reminder card 4 days before the appointment (IG3),no further reminder (IG1),,,binary,94,102,84,104,,,,,,,1.02876872,0.19754306,0.13189607,0.00312375,found in text as fractions of group sizes,FALSE,FALSE,FALSE,TRUE,"10,493",TEST,DP
690,13830,4210722,vaccination certificates were submitted,a separate reminder card 4 days before the appointment (IG3),reminder card together with the appointment letter (IG2),,,binary,94,102,91,107,,,,,,,0.72558246,0.20912731,0.0802913,0.00247759,found in text as fractions of group sizes,FALSE,FALSE,FALSE,TRUE,"10,493",TEST,DP
691,13831,4210722,use of a reminder card,a separate reminder card 4 days before the appointment (IG3); reminder card together with the appointment letter (IG2);,no further reminder (IG1),no significant difference,0,binary,185,209,84,104,,,,,,,0.60721747,0.10897683,0.09159567,0.00291009,found in text as fractions of group sizes,FALSE,FALSE,FALSE,TRUE,"10,493",TEST,DP
692,5635,5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),Duloxetine (D),significantly increased,1,continuous,,30,,30,137,61.3,91.7,35.5,0.89262531,0.0733065,,,,,found in fig2,TRUE,FALSE,FALSE,TRUE,"6,401",TEST,DP
693,5636,5712123,postoperative pain at rest,duloxetine 60 and etoricoxib 120mg (group D/E),placebo,significantly decreased,-1,continuous,,30,,30,2,,3,,cannot calculate,cannot calculate,,,,,values given as score (range),FALSE,TRUE,FALSE,FALSE,"6,401",TEST,DP
694,5636,5712123,postoperative pain on movement,duloxetine 60 and etoricoxib 120mg (group D/E),placebo,significantly decreased,-1,continuous,,30,,30,3.5,,3,,cannot calculate,cannot calculate,,,,,values given as score (range),FALSE,TRUE,FALSE,FALSE,"6,401",TEST,DP
695,5639,5712123,morphine requirements,E group,P group,significantly decreased,-1,continuous,,30,,30,24.6,4.5,31.9,6.7,-1.2625038,0.0799493,,,,,found in fig3,TRUE,FALSE,FALSE,TRUE,"6,401",TEST,DP
696,5639,5712123,morphine requirements,D group,P group,significantly decreased,-1,continuous,,30,,30,22.6,4.1,31.9,6.7,-1.6526241,0.08942639,,,,,found in fig3,TRUE,FALSE,FALSE,TRUE,"6,401",TEST,DP
697,5639,5712123,morphine requirements,D/E group,P group,significantly decreased,-1,continuous,,30,,30,17.9,3.2,31.9,6.7,-2.6318902,0.12439038,,,,,found in fig3,TRUE,FALSE,FALSE,TRUE,"6,401",TEST,DP
698,5637,5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),Placebo group (P),significantly increased,1,continuous,,30,,30,137,61.3,62,37.2,1.45998637,0.08442967,,,,,found in fig2,TRUE,FALSE,FALSE,TRUE,"6,401",TEST,DP
699,5638,5712123,time to first rescue analgesic,duloxetine 60 and etoricoxib 120mg (group D/E),etoricoxib (E),significantly increased,1,continuous,,30,,30,137,61.3,105.3,28.4,0.6549502,0.07024133,,,,,found in fig2,TRUE,FALSE,FALSE,TRUE,"6,401",TEST,DP